

Review

Bioactive Compounds from Marine Sponges: Fundamentals and Applications

Disha Varijakzhan ¹, Jiun-Yan Loh ², Wai-Sum Yap ², Khatijah Yusoff ³, Rabiha Seboussi ⁴, Swee-Hua Erin Lim ⁵, Kok-Song Lai ^{5,*} and Chou-Min Chong ^{1,6,*}

- ¹ Aquatic Animal Health and Therapeutics Laboratory, Institute of Bioscience, Universiti Putra Malaysia, Serdang 43400, Malaysia; dishavarijakzhan@gmail.com
- ² Faculty of Applied Sciences, UCSI University, No. 1, Jalan Menara Gading, UCSI Heights, Cheras, Kuala Lumpur 56000, Malaysia; lohjy@ucsiuniversity.edu.my (J.-Y.L.); wsyap@ucsiuniversity.edu.my (W.-S.Y.)
- ³ Department of Microbiology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Serdang 43400, Malaysia; kyusoff@upm.edu.my
- ⁴ Health Sciences Division, Al Ain Men's College, Higher Colleges of Technology, Al Ain 17155, United Arab Emirates; rseboussi@hct.ac.ae
- ⁵ Health Sciences Division, Abu Dhabi Women's College, Higher Colleges of Technology, Abu Dhabi 41012, United Arab Emirates; lerin@hct.ac.ae
- ⁶ Department of Aquaculture, Faculty of Agriculture, Universiti Putra Malaysia, Serdang 43400, Malaysia
- * Correspondence: lkoksong@hct.ac.ae (K.-S.L.); choumin@upm.edu.my (C.-M.C.)

Abstract: Marine sponges are sessile invertebrates that can be found in temperate, polar and tropical regions. They are known to be major contributors of bioactive compounds, which are discovered in and extracted from the marine environment. The compounds extracted from these sponges are known to exhibit various bioactivities, such as antimicrobial, antitumor and general cytotoxicity. For example, various compounds isolated from *Theonella swinhoei* have showcased various bioactivities, such as those that are antibacterial, antiviral and antifungal. In this review, we discuss bioactive compounds that have been identified from marine sponges that showcase the ability to act as antibacterial, antiviral, anti-malarial and antifungal agents against human pathogens and fish pathogens in the aquaculture industry. Moreover, the application of such compounds as antimicrobial agents in other veterinary commodities, such as poultry, cattle farming and domesticated cats, is discussed, along with a brief discussion regarding the mode of action of these compounds on the targeted sites in various pathogens. The bioactivity of the compounds discussed in this review is focused mainly on compounds that have been identified between 2000 and 2020 and includes the novel compounds discovered from 2018 to 2021.

Keywords: marine sponge; bioactive compounds; microbial symbionts; antimicrobial activity; aquaculture; quorum quenching



Citation: Varijakzhan, D.; Loh, J.-Y.; Yap, W.-S.; Yusoff, K.; Seboussi, R.; Lim, S.-H.E.; Lai, K.-S.; Chong, C.-M. Bioactive Compounds from Marine Sponges: Fundamentals and Applications. *Mar. Drugs* **2021**, *19*, 246. <https://doi.org/10.3390/md19050246>

Academic Editor: Vida Šimat

Received: 29 March 2021

Accepted: 22 April 2021

Published: 27 April 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

The open oceans and deep seas cover about 70% of the earth's surface and are a natural habitat to approximately 80% of the world's plant and animal species [1,2]. The ocean is known to accommodate various living organisms, ranging from prokaryotic bacteria and marine invertebrates to multicellular complex organisms such as sharks and whales [3]. Despite the extreme conditions of the marine environment, the accessibility of new compounds from marine organisms from the various depths of the sea is now possible due to the advancement in technologies such as scuba diving equipment, remotely operated vehicles, closed-circuit computerized mixed gas rebreathers and manned submersibles [4,5]. More than 5000 novel natural products have been extracted from marine organisms living in these extreme environments, having a wide thermal range from freezing temperatures

to as high as 350 °C in deep hydrothermal vents, pressures ranging from 1 to 1000 atm, varying nutrient ranges and photic and non-photoc zones [6,7].

Research involving natural compounds from marine organisms began in the 1950s with Bergmann and coworkers' discovery of the compounds spongouridine and spongouridine (Figure 1), extracted from the Caribbean sponge *Tectitethya crypta* (de Laubenfels, 1949) [4]. In the past few years, several marine taxa, such as sea slugs, sponges and soft corals, have been a major source of novel natural bioactive compounds [8–10]. From the initial stage of natural product marine research to the current trend of drug discovery, most of the natural compounds that have been discovered are from marine invertebrates, especially marine sponges, with hundreds of compounds discovered yearly from this source [3,11]. Figure 2 below showcases the data that were retrieved from <https://www.lens.org/> using keywords “marine sponge” and “bioactive compounds”, illustrating the publication of scholarly works regarding the discovery of marine sponge-derived compounds and their application in the form of books, book chapters, journal articles, conference proceedings, dissertations and patents. A sponge is an invertebrate, sessile organism that can be widely found in temperate, tropical and polar habitats [4,12]. Marine sponges belong to the phylum Porifera, and there are more than 8000 species of sponges that have been discovered so far [11].




Figure 1. Chemical structures of (a) spongouridine and (b) spongouridine [13].









Figure 2. Publication of scholarly works (books, book chapters, journal articles, conference proceedings, dissertations) and patents that reported the discovery and/or applications of marine sponge-derived bioactive compounds retrieved from <https://www.lens.org/> using keywords “marine sponge” and “bioactive compounds”.

Marine sponges are made up of a jelly-like layer between two thin layers of cells and might contain the skeleton of spicules made of silica, calcium carbonate, and a protein known as spongin [14]. The identification of sponge species is based on the size and shape of the spicules [14]. Marine sponges are filter feeders; they cope with potentially hazardous particles by producing neutralizing bioactive compounds. Around 11 genera of sponges have been discovered to contribute to the discovery of bioactive compounds, including the three genera *Haliclona*, *Petrosia* and *Discodemia*, which are known to produce compounds with powerful anti-inflammatory and anti-cancer activities [7,15]. Bioactive compounds synthesized by sponges are chemically diverse and can be grouped as nucleosides, terpenes, sterols, cyclic peptides and alkaloids [11]. This diverse range of bioactive compounds are not completely synthesized by sponges alone but are also synthesized by their microbial symbionts [3,14]. Table 1 below lists a few marine sponge species and their bioactivities, along with the chemical structure of the compounds.

Table 1. Compounds isolated from marine sponges and their bioactivity.

Marine Sponge	Compound	Bioactivity	References
<i>Agelas oroides</i> (Schmidt, 1864) associated with <i>Streptomyces</i> sp. SBT345	 <p>Compound quinolone ageloline A</p>	<ul style="list-style-type: none"> Inhibitory activity towards <i>Chlamydia trachomatis</i> and cytotoxic activity against leukemia cells HL-60 	[16,17]
<i>Dysidea avara</i> (Schmidt, 1862)	 <p>6'-Hydroxy avarol (R1: OH)</p>  <p>3'-hydroxy avarone (R1: OH)</p>	<ul style="list-style-type: none"> Antiviral activity against Human Immunodeficiency virus (HIV) 	[18,19]
<i>Hamigera tarangaensis</i> (Bergquist and Fromont, 1988)	 <p>Compound Hamigeran B</p>	<ul style="list-style-type: none"> Antiviral activity against herpes and polio virus 	[20,21]
<i>Leuconia nivea</i> (Grant, 1826) Synthesized by the symbiont bacteria <i>Microbulbifer</i> sp.	 <p>Natural paraben (R:-(CH₂)₉ -(CH₃))</p>	<ul style="list-style-type: none"> Antibacterial activity against <i>Staphylococcus aureus</i> 	[17,22]

In this review, we discuss the antimicrobial potential in human diseases of various bioactive compounds extracted from marine sponges and the application of these compounds in the aquaculture industry. The application of these compounds in other veterinary commodities is further discussed alongside the mode of action of these bioactive compounds on their targeted sites. In this review, we will be focusing on the compounds extracted from the extracts isolated during the period 2000 to 2020.

2. Ecological and Biological Factors Driving the High Abundance of Bioactive Compounds from Marine Sponges

Marine sponges have two different life cycles. At the initial stage, a larva is released from the female sponge into the water; it will eventually attach to a suitable substrate and will grow into a non-motile (sessile) adult [23]. Marine sponges are known as excellent filter feeders; the surrounding water is drawn into the sponge through small pores known as ostia, and the water is ejected through a larger opening known as osculum [24].

There are specific cells present in the marine sponge that perform particular functions. Flagellated cells (choanocytes) allow water movement in one direction through the coordination of the flagella. Particulate matter present in the water is engulfed by the amoebocyte cells [25]. Figure 3 below depicts the ecological and life-history-related factors that drive the high production of bioactive compounds in marine sponges.




Figure 3. A summary of ecological and life-history-related factors that cause high production of bioactive compounds in marine sponges. (a) The larval stage is highly motile; hence, the larva is exposed to a high variety of pathogenic and abiotic stressors. (b) The non-motile adult experiences high competition for space among sessile organisms and predation by natural predators. Adults have symbionts attached to them. Filter feeding behavior of the adult increases the risk of exposure to hazardous materials. Overgrowing by fouling organisms like barnacles on the marine sponge has a lethal effect by blocking ostia. These factors have driven the high production of bioactive compounds in marine sponges.

Microorganisms passed through the ostia remain in the mesohyl, which is the inner sponge of the tissue, thus forming a symbiotic interaction with the sponge. The symbionts consist mainly of bacteria but also archaea, eukaryotes or larger organisms [26]. The bacterial population found in the extracellular mesohyl matrix of the sponges harbors dense bacterial assemblages that could make up to 38% of the biomass of the sponge [23,27,28]. In some sponges, the bacterial density may even range up to 10^8 to 10^{10} or 10^5 to 10^6 bacteria/g of the sponge's wet weight [29]. Due to the difference in range between microbial

population densities, marine sponges can be classified as “bacteriosponges” or “highly-microbial-abundance (HMA) and low-microbial-abundance (LMA)” sponges [23,29].

The ecological and evolutionary importance of the associations between sponge and microorganism can be determined by their ability to produce various bioactive compounds, which can be utilized in the biotechnology industry [30]. The advantage of secondary metabolites in the sponges can be identified based on the presence of antifouling products. For example, sponges can protect the water-pumping ability by preventing biofilm formation and the settlement of barnacles or bryozoans on their surface [31,32]. Sponges produce high-level cytotoxic chemicals by producing mucus-containing toxins, which create a clear zone around the sponge as a defense against other marine species. This ensures that sponges are able to conquer densely populated rocks or corals, enabling them to compete with organisms that grow rapidly. However, they are also able to selectively use these toxins without destroying themselves [30].

Secondary bioactive metabolites found in marine sponges are generally of microbial origin [33–35]. This can be proven through the structural similarity of some of the natural products that have been discovered from the sponges, such as complex polyketides and non-ribosomal peptides, which are exclusively known to microorganisms. However, some metabolites are produced by the sponges. For example, avarol is a compound found in the sponge *Dysidea avara*, stevensine is from *Axinella corrugate* (George and Wilson, 1919) and an array of cytotoxic brominated isoxazoline alkaloids are the natural products of the sponges themselves [36–38]. In addition, some enzymes with potential therapeutic applications have been isolated from sponges. For instance, ATP N-glycosidase is an enzyme discovered in *Axinella polypoides* (Schmidt, 1862) that converts adenosine-5'-triphosphate (ATP) into adenine and ribose-5-triphosphate [39]. The hydrolysis of ATP takes place by hydrolyzing the N-glycosidic bond that exists in the ATP molecule, thus leaving the energy-rich triphosphate moiety. The cleavage results in ribose-5-phosphate, which is utilized in the synthesis of nucleic acids deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) [40].

3. Chemistry of Compounds from Marine Sponges

The extracts obtained from marine sponges consist of a collection of secondary metabolites that are synthesized by the sponges and also by the symbionts attached to the sponges [17,41]. These secondary metabolites synthesized by the sponges and the symbionts function as a defense mechanism; the synthesis of these metabolites depends on various stress factors, such as predators, overgrowth of fouling organisms and competition for space with other organisms [3,42]. These secondary metabolites are chemically diverse, and there are various factors that influence the compounds that can be extracted from the marine sponges [3,43]. For example, sponges from the genus *Haliclona* synthesize a wide range of metabolites ranging from class terpenes, such as sterols, sesquiterpenoid quinols, glycosphingolipids, and alkaloid bioactive secondary metabolites [44]. Table 2 below shows examples of compounds from marine sponges and the chemical structure of such compounds. The extraction process applied to obtain the compounds will be discussed further, including the parameters that affect the extraction and the types of extraction that can be applied.

Table 2. Compounds extracted from marine sponges and the chemical structure of the compounds.






Marine Sponge	Classification	Compound	Chemical Structure	References
<i>Agelas oroides</i> (Schmidt, 1864)	Bromopyrrole alkaloid	Oroidin		[3,45]
<i>Discodermia kiiensis</i> (Hoshino, 1977)	Peptide	Discodermin A		[46]
<i>Jaspis stellifera</i> (Carter, 1879) <i>Stelletta tenuis</i> (Lindgren, 1897)	Triterpene	Stelletin A		[47]

Table 2. Cont.

<i>Haliclona</i> sp.	Polycyclic, β -carboline-derived alkaloid	Manzamine A		[48,49]
<i>Luffariella variabilis</i> (Polejaeff, 1884)	Sesterterpene	Manoalide		[50]

3.1. Extraction Process

The extraction process is a step that involves the separation of the desired natural products from the raw materials, i.e., the marine sponges [51]. Various methods can be applied to obtain the crude extract [52]. The crude extract is known to be composed of a complex mixture of various metabolites, including alkaloids, terpenoids, peptides and quinones [53,54]. The extraction process can be divided into two categories, which are the traditional extraction method and newly emerging technologies based on the energy or mechanism [52].

3.1.1. Traditional Extraction Method

The traditional extraction method consists primarily of extraction via solvent or solid-liquid extraction [52]. The Soxhlet method involves boiling the sample along with the solvent, with or without stirring, for a certain duration, whereas maceration involves the sample being soaked in the solvent and stirring from time to time [55]. These techniques are examples of solid-liquid extraction methods that can be practiced. These methods have been practiced widely for a long period. However, there are few disadvantages to applying these techniques, which include that they are time-consuming, they require a large volume of solvents, there can be a loss of compounds during the concentration step due to volatilization, there can be hydrolysis of the compounds due to harsh conditions such as high temperature, and solvent wastes can cause environmental pollution [56].

The solvents used in these techniques consist of either a single solvent or a mixture of solvents with a wide range of polarity [57,58]. For example, methanol, ethanol, trichloromethane, acetone and water can be utilized individually as a solvent or they can be utilized with a mixture of organic solvents such as ethanol and acetone [59,60].

3.1.2. Emerging Technology

As there are various limitations to the traditional extraction method, new methods are being practiced that are less time-consuming and that have been found to be more efficient in the extraction process. Microwave-assisted extraction (MAE), ultrasound-assisted extraction (UAE) and pressurized solvent extraction (PSE) are few new techniques that are being widely used as alternative extraction procedures [52,56].

MAE is a technique that utilizes microwave irradiation to speed up the removal of various compounds from the natural matrices [52]. In this method, both heat and mass gradients work in the same direction; that is, friction between the polar molecules results in heat production within the matrix [61,62]. The friction between the molecules is caused by the electric field, resulting in the vibration and or oscillation of the molecules and causing inter- and intra-molecular friction [56]. This results in rapid heating (in seconds) of the matrix, leading to the pressurized effect and causing rupture of the cell wall and membrane. As a consequence, the transfer rate of the compounds from the cells to the solvent occurs at a faster rate [52].

UAE is another technique that utilizes ultrasound waves to alter the physical and chemical properties after interacting with the material [63,64]. The advantages of the technique are that it reduces the extraction duration significantly while simultaneously increasing the extraction yield [65]. This can be achieved due to the formation of cavitation bubbles in the solvent [65]. The cavitation bubble is known to be formed in the liquid during the expansion phase. The ability to form a cavitation bubble depends on the characteristics of the ultrasound wave, the property of the solvents, and the surrounding conditions [66,67]. After a cavitation bubble is formed, it collapses during the compression cycle, resulting in the liquid molecules being pushed together and creating a high-speed micro-jet that moves towards the matrix particle and results in the mixture of the solvent with the matrix [61,66]. In this procedure, the pressure and temperature can reach up to 1000 bar and 4726.85 °C, respectively [66,67]. This results in the breakage of the cell wall

and membranes, thus allowing the solvent to penetrate the solid particle easily, releasing the intracellular compounds.

PSE is one of the emerging techniques that utilizes temperature and pressure ranging from 50–200 °C and 35–200 bars, respectively. The temperature and pressure applied in this procedure are set to be lower than the critical temperature (T_c) and critical pressure (P_c) of the solvents being used; hence, the solvents stay in the liquid state [68,69]. The high pressure applied in the procedure results in the rise of the solvent above its boiling temperature; this increase in temperature enhances the solubility and mass transfer rate and simultaneously reduces the viscosity and the surface tension of the solvent [69,70]. The most commonly used solvent in this procedure consists of water, propane and dimethyl ether [60–62].

3.1.3. Factors Affecting the Extraction

The extraction process of the bioactive metabolites from marine sponges depends on the type of extraction process that will be applied along parameters such as solvent polarity, temperature and pressure [53,71]. These factors influence the types of metabolites found predominantly in the crude extract. The type of solvents used for extraction can be categorized based on polarity, ranging from non-polar solvents such as hexane and trichloromethane to the highly polar solvent of water [54,72]. A mixture of water and an organic solvent such as ethanol will result in an increase in the yield of phenolic compounds compared to the percentage yield when the solvents are used individually [52].

A study was conducted to identify the influence of the solvents on the percentage yield of the crude extracts by testing the sponges *Stylorella aurantium* (Kelly-Borges and Bergquist, 1988) and *Haliconia molitba* (de Laubenfels, 1949) using methanol and water as solvents [73]. The methanol extract of both the sponges exhibited a better antimicrobial activity against *B. cereus* compared to the water extract; however, the water solvent extract of both the sponges exhibited a higher percentage yield. The difference in the yield percentage between the two solvents is due to the polarity. As water is higher in polarity compared to methanol, more polar compounds from the sponges can be extracted, thus increasing the yield percentage [73]. The difference in the antimicrobial activity between the crude extracts suggests that the bioactive compounds that are responsible for the inhibition of the bacterial cell growth are mostly semi-polar; thus the extraction of these compounds was possible with methanol, as it is a semi-polar solvent.

A study was conducted on the marine sponge *Xestospongia* sp. (Laubenfels, 1932) by Bayona et al. (2018) looking at the correlation between the parameter pressure, temperature and solvent polarity and the diversity in the extracted compounds [53]. It was found that the solvent polarity and temperature applied during the extraction process are the most important factors influencing the metabolic diversity in the extract. As mentioned above, an increase in the solvent polarity was found to be positively correlated with the diversity in the compounds extracted. Ethanol was found to be a more suitable solvent, as it resulted in a wide range of compounds compared to the solvent with a mixture of ethanol and dichloromethane. The ethanol solvent was identified to be more proficient in the extraction of polar compounds and also lipophilic fatty acid compounds, thus resulting in a wide range of yield. When the solvent dichloromethane was used, the extract was found to contain compounds belonging to sterols and fatty acids.

However, when the extraction was conducted at a higher temperature (60–80 °C), there was a reduction in the chemical diversity compared to the lower temperature (30–50 °C). The extraction was performed using 100% ethanol to determine the effect of the temperature [53]. The extraction at different temperature ranges resulted in a specific group of compounds being extracted. At the high temperature, specific groups such as aromatic-based compounds were extracted efficiently, whereas at low temperatures, the extracts were identified to contain significant chemical diversity.

Another factor that was reported to significantly influence extraction was the number of cycles used to perform the extraction; this showed an interaction with the temperature

at which the extraction process was conducted [53]. The study found that there was no difference in the diversity of compounds obtained when the extraction was performed at low temperature and one or three cycles. However, when the temperature was increased, the diversity in the extract decreased when one cycle was used, though increasing the number of cycles increased the compound diversity.

3.2. Classification of Compounds

While the crude extract of known organisms has been identified to contain a wide range of compounds from various chemistry classes, three major classes have been predominantly identified among the marine sponge extracts. A few examples of compounds extracted from sponges will be discussed in this review.

3.2.1. Terpenes

Secondary metabolites consist of terpenes in a large number, where they are synthesized in the form of polymers of isoprene (C_5H_8), joined in a repetitive head-to-tail manner [3,74,75]. The modification in the structures of terpene-based metabolites results in a diverse range of derivatives, where there is a wide range of chemical structure and, at the same time, biological properties. Terpenes have an incredible range of structures that can be extracted based on the polarity of the solvent [76]. The terpenes consist of non-polar terpenes, which are linear and cyclized terpenes, and polar terpenoids. The first terpene that was discovered in the marine sponge was steroidal terpenoids. Sesterterpenoid (C25) and triterpenoids (C30) are two major classes of terpenoids that have been commonly isolated from marine sponges and are known to have various bioactivities [42,77].

For example, manoalide is a parent compound of various sponge metabolites belonging to the sesterterpene class and was isolated from sponge *L. variabilis* in Palau [50]. The compound exhibited various bioactivities, such as antibacterial activity against *Streptomyces pyogenes* and *S. aureus*, and is a potent inhibitor of phospholipase A2 (PLA2) enzyme, which is responsible for providing a substrate of pro-inflammatory mediators [78,79]. Furthermore, it was found that the compound manoalide and its analogues' bioactivities are contributed by the presence of various functional groups in the compounds [3].

Isomalabaricanes are triterpenes that were first identified from sponges *Jaspis stellifera* (Carter, 1879) in Fiji and *Stelletta* sp. (Schmidt, 1862) in Somalia [80,81]. The isomalabaricane triterpenes can be classified into three groups based on the presence of polyene conjugated functionality: (i) stelletins, which possess γ -pyrone; (ii) stelliferins, which can be oxygenated at C-22; (iii) globostellatic acids, which have a carboxyl group at C-4 [3]. Stelletins isolated from marine sponges such as *J. stellifera* and *Stelletta tenuis* (Lindgren, 1897) have exhibited cytotoxic activity against cancer cells such as murine leukemia P388 cell lines [47].

3.2.2. Alkaloids

Alkaloid-based compounds are another class of metabolites that have been extensively identified from marine sponges. The manzamines are polycyclic, β -carboline-derived alkaloids; manzamine A was the first isolated from marine sponge *Haliclona* sp. in 1986. The manzamine compounds are characterized by a fused and bridged tetra- or pentacyclic ring system linked to the β -carboline [48]. The manzamine alkaloids have various bioactivities, such as antibacterial, anti-malarial and cytotoxic [82,83].

Furthermore, bromopyrrole alkaloids contain compounds that can only be found among marine sponges. Oroidin was the first compound isolated from this group, being isolated from *Agelas oroides* (Schmidt, 1864) in 1971. For the compounds classified as bromopyrrole alkaloids, oroidin is the precursor, as these compounds contain a pyrrole-imidazole unit that is a derivative of oroidin [3,45]. Hymenidin, clathrocin and sventrin are examples of bromopyrrole alkaloids that have been isolated from marine sponges, where the bioactivity is attributed to the bromination pattern of the pyrrole moiety [3].

3.2.3. Peptides

Bioactive peptides are a well-established sector of marine natural product-based research, and the peptides from marine sponges have been discovered to contain unique structures compared to the bioactive peptides from different sources. These peptides are cyclic or linear in shape and have amino acids that are either rare or absent in terrestrial-based and microbial peptides [84,85]. Peptides isolated from marine sponges are known to be safe, inexpensive and having a wide range of antimicrobial properties [86].

Antimicrobial peptides (AMPs) are an important source of new antibiotics, which can be used as an alternative to the available antibiotics or in combination with these antibiotics [87]. An example of AMP would be Discodermin A, a tetra-decapeptide; it is the first bioactive peptide isolated from *Discodermia kiiensis* (Hoshino, 1977) from Shikine Island, Japan [46]. Further investigation has resulted in the discovery of various analogues, including discodermin B, C and D [88,89]. Discodermins A–D has exhibited antibacterial activity and is also a potent inhibitor of enzyme PLA2 [3,90]. Tetra-decapeptide AMPs are characterized based on the presence of anomalous amino acid residues, which include formyl-D alanine, 3-methyl-L-proline, and 3-methyl-D-valine [87]. The genus *Theonella* (Gray, 1868) is known as a source of unusual peptides, such as Theonellamide F, which is a bicyclic peptide consisting of a histidino-alanine bridge and exhibiting antifungal properties against various pathogenic fungal strains, such as *Candida* sp., *Trichophyton* sp. and *Aspergillus* sp. [91].

Other examples of peptides are the proline-rich cyclopeptides, which exhibit bioactivities such as anti-cancer, immunosuppressor, and as anti-inflammatory [87]. The proline residue found in the peptide molecules is important for structural stability by reducing the conformational flexibility. This is due to the rigidity provided by the proline ring, leading to the maintenance of the rigid structure of the peptide [65]. Examples of proline-rich cyclopeptides are Callyaerins A–F and H, which are extracted from ethyl acetate extract of marine sponge *Callyspongia aerizusa* (Desqueyroux-Faùndez, 1984) [87]. One of the compounds, Callyaerin A, showed potent antifungal activity against *Candida albicans*.

4. Bioactivities of Marine Sponges With Regard to Human Diseases

In recent years, the research community has been focused on finding alternatives to overcome increasing cases of antimicrobial-resistant microorganisms such as bacteria and fungus [75,92]. Natural products from plants and microorganisms are seen as an alternative to overcome antimicrobial resistance [93]. Similarly, marine organisms—especially sponges—have been reported to synthesize bioactive compounds that have antimicrobial activity. For example, the marine species belonging to the genus *Erylus* (Gray, 1867) from the Mediterranean Sea and the Atlantic and Pacific Oceans are found to be able to synthesize glycolipids, which are capable of inhibiting the growth of bacteria, fungi and viruses, including HIV [94]. Table 3 summarizes various antimicrobial activities from different marine sponges. In the following subsections, the antimicrobial activities of marine sponge bioactive compounds will be discussed.

Table 3. Marine sponges and extracted compounds having antimicrobial activity.

Bioactivity	Marine Sponge	Compound	Properties	References
Antibacterial	<i>Axinella donnani</i> (Bowerbank, 1873)	• Lectin	• High potency in anti-biofilm activity against biofilm-producing <i>S. aureus</i> and able to inhibit the bacterial cells of <i>S. aureus</i> .	[95]
	<i>Clathria compressa</i> (Schmidt, 1862)	• Clathric acid	• Able to inhibit growth of methicillin-resistant <i>S. aureus</i> ATCC 33,591 (MRSA), <i>S. aureus</i> ATCC 6538P and vancomycin-resistant <i>S. aureus</i> (VRSA).	[96]
	<i>Siliquariaspongia</i> sp. (Hoshino, 1981)	• Motualevic acid A • Motualevic acid B • Motualevic acid E • Motualevic acid F	• Compounds motualevic acid A and B exhibited potent activity against <i>S. aureus</i> at a concentration of 10 µg. • Motualevic acid A exhibited antibacterial activity against MRSA at 10 µg. • Motualevic acid E exhibited weak antibacterial activity against <i>S. aureus</i> at 50 µg. • Motualevic acid F exhibited potent antibacterial activity against both <i>S. aureus</i> and MRSA at concentrations of 2 µg and 5 µg, respectively.	[97]
Antiviral	<i>Aaptos aaptos</i> (Schmidt, 1864)	• 2-isopropyl-10-methoxyimidazo[4,5,1- <i>ij</i>]pyrido[2,3,4- <i>de</i>]quinolone. • 2-(phenethylamino) demethyl(oxy)aaptamine. • 3-(isopentylamino) demethyl(oxy)aaptamine.	• The compounds 2-isopropyl-10-methoxyimidazo[4,5,1- <i>ij</i>]pyrido[2,3,4- <i>de</i>]quinolone, 2-(phenethylamino) demethyl(oxy)aaptamine and 3-(isopentylamino) demethyl(oxy)aaptamine inhibited HIV-1 virus replication by 27.7%, 88% and 72.3%, respectively.	[98]
	<i>Dactylospongia metachromia</i> (de Laubenfels, 1954)	• Metachromin A	• Inhibit the Hepatitis B viral production significantly at an EC50 of 0.8 µM.	[99]
	<i>Stachybotri</i> sp. HH1 ZSDS1F1-2 fungal strain from unknown marine sponge	• Stachybogrisephenone B • Grisephenone A • 3,6,8-trihydroxy-1-methylxanthone	• Antiviral activity against the intestinal virus Enterovirus 71 (EV71).	[100]

Table 3. Cont.

Bioactivity	Marine Sponge	Compound	Properties	References		
Antifungal	<i>A. aaptos</i>	<ul style="list-style-type: none"> • Methylethylketal derivative of dimethyl(oxy)aaptamine • 2-(phenethylamino) demethyl(oxy)aaptamine. • 3-(isopentylamino) demethyl(oxy)aaptamine 	<ul style="list-style-type: none"> • The compound methylethylketal derivative of dimethyl(oxy)aaptamine exhibited antifungal activity against <i>Candida parapsilosis</i>. • Compound 2-(phenethylamino) demethyl(oxy)aaptamine exhibited antifungal activity against <i>C. albicans</i>, <i>C. parapsilosis</i>, <i>Cryptococcus neoformans</i>, <i>Trichophyton rubrum</i> and <i>Microsporum gypseum</i> at 32, 64, 32, 4, and 16 µg/mL, respectively. • 3-(isopentylamino) demethyl(oxy)aaptamine exhibited antifungal activity against <i>C. neoformans</i>, <i>T. rubrum</i>, and <i>M. gypseum</i> with MIC of 64, 8, and 32 µg/mL, respectively. 	[98]		
			<i>Hippospongia</i> sp. (Schulze, 1879)	<ul style="list-style-type: none"> • <i>epi-ilimaquinone</i> 	<ul style="list-style-type: none"> • The compound exhibited potent antifungal activity against amphotericin-resistant <i>C. albicans</i> with a MIC value of 125 µg/mL. 	[101]
			<i>Xestospongia exigua</i> (Kirkpatrick, 1900)	<ul style="list-style-type: none"> • Xestodecalactone B 	<ul style="list-style-type: none"> • The extract was able to inhibit the growth of <i>C. albicans</i>. 	[102]
Anti-parasite	New Caledonian deep sea sponge <i>Verongula rigida</i> (Esper, 1794)	<ul style="list-style-type: none"> • Meroterpenes • Alisiaquinone A • Alisiaquinone B • Alisiaquinone C • Alisiaquinol • 11-hydroxyaerotherionin • Puralidin B • Aeroplysinin-A 	<ul style="list-style-type: none"> • Exhibited anti-malarial activity against chloroquinone-resistant <i>Plasmodium falciparum</i> strain. • 11-hydroxyaerotherionin exhibited leishmanicidal activity against <i>Leishmania</i>. • Compound purealidin B showcased anti-malarial activity against <i>P. falciparum</i> strain. • Compound aeroplysinin-A inhibit the growth of the parasite <i>Trypanosoma cruzi</i>. • All the compounds with anti-parasitic activity were found to be bromotyrosines. 	[103,104]		

4.1. Antibacterial Activity

In general, bacteria can be categorized based on the cell wall structure, which is Gram-positive or Gram-negative [105,106]. Gram-positive bacterial cell walls comprise a thick peptidoglycan layer containing teichoic acid, lipoteichoic acid and proteins embedded within the peptidoglycan layer, whereas Gram-negative bacteria have a thinner peptidogly-

can layer surrounded by an outer membrane layer containing lipopolysaccharides [75,107]. Despite the differences in structure, there are various compounds isolated from marine sponges that have been shown to exhibit antibacterial properties against pathogenic human bacterial strains such as *S. aureus*, *Escherichia coli* and *Pseudomonas aeruginosa*. In general, bioactive compounds may cause death through the leakage of the contents in the bacterial cells due to disruption of the cell membrane through the generation of reactive oxygen species (ROS). ROS is also able to oxidize the proteins found within the bacterial cells by altering the covalent bonds that are responsible for maintaining the structure of the proteins essential for the survival of the cells [108,109].

Clathric acid, a bicyclic terpenoid, was isolated from *Clathria compressa* collected from Florida, USA. It exhibited antibacterial activity when tested against methicillin-resistant *S. aureus* ATCC 33,591 (MRSA), *S. aureus* ATCC 6538P and vancomycin-resistant *S. aureus* (VRSA) bacterial strains with MIC values of 64 µg/mL, 32 µg/mL and 64 µg/mL, respectively [96].

Lectin is a glycoprotein compound found in *Axinella donnani*. It showed high potency in anti-biofilm activity against biofilm-producing *S. aureus* and at the same time showed antibacterial activity against *S. aureus* bacterial cells [95]. The total biomass of the biofilm was reduced in a concentration-dependent manner after being treated with lectin at a concentration of 15.1 µg/mL to a concentration as high as 1000 µg/mL; the treatment at 1000 µg/mL showcased an inhibition of more than 80%.

However, some of the marine sponge compounds were found to be less potent in Gram-negative bacterial strains. For example, clathric acid isolated from *C. compressa* did not exhibit any antibacterial activity at a concentration of 128 µg/mL when tested against *Escherichia coli* and *Klebsiella pneumoniae*; however, as stated above, the compound exhibited antibacterial activity against Gram-positive bacteria [96]. The extracts that were found to exhibit antibacterial activity against Gram-negative bacteria are the compound lectins extracted from *A. donnani*, which simultaneously exhibited anti-biofilm activity against Gram-negative bacterial strains *E. coli*, *K. pneumoniae* and *Pseudomonas aeruginosa* and potent anti-biofilm activity against biofilm-producing *P. aeruginosa* [95]. Similarly, extract from *Haliclona* also exhibited antibacterial activity against Gram-negative bacterial strains *E. coli* and *P. aeruginosa*, with the same potency as the Gram-positive bacterial strains [110].

The compound nagahamide A is a depsipeptide that is isolated from *Theonella swinhoei* (Gray, 1868). The compound was found to exhibit a weak antibacterial activity against *E. coli* and *S. aureus* [111]. Nagelamides Q and R are dimeric bromopyrrole alkaloids isolated from *Agelas* sp.; they were found to exhibit antibacterial activity. The compound nagelamide Q was found to contain a pyrrolidine ring, whereas nagelamide R would be the first bromopyrrole alkaloid containing an oxazoline ring [112]. Both the compounds exhibited significant inhibition against *B. subtilis*, with an MIC value of 13.0 µg/mL, whereas both the compounds exhibited activity against *E. coli*, *M. luteus* and *S. aureus* at concentrations greater than 25 µg/mL.

Compounds such as a bisindole alkaloid 2,2-bis(6-bromo-3-indolyl)ethylamine and its synthetic analogues were able to exhibit antibacterial activity and simultaneously inhibit the formation of biofilm. The compound 2,2-bis(6-bromo-3-indolyl)ethylamine, isolated from the New Calodonian sponge *Orin asp.* (Gray, 1867), exhibited significant antibacterial activity against *E. coli*, *S. aureus* and *K. pneumoniae* with an MIC concentration as low as 8 mg/L. The compound was also found to be able to inhibit the biofilm formation simultaneously by 82.2% and disaggregate the biofilms of the *E. coli*, *S. aureus*, and *K. pneumoniae* pathogens [113].

4.2. Antiviral Activity

Viruses are obligate intracellular parasites that are small in size and contain a genome, either RNA or DNA surrounded by a protective layer known as a virus-coded protein coat [114]. Over the centuries, viruses have been responsible for various diseases, such as chicken pox, AIDS, SARS and measles as well as the current pandemic causative agent for

severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [115]. Various bioactive compounds extracted from marine sponges showed antiviral effects against herpes simplex virus and Hepatitis A virus.

Compounds stachyobogrisphenone B, grisphenone A, and 3,6,8-trihydroxy-1-methylxanthone are compounds that were isolated from a fungal strain, *Stachybotry* sp. HH1 ZSDS1F1-2, which was isolated from a marine sponge from Xisha Island, China [100]. The compounds exhibited antiviral activity against the intestinal virus Enterovirus 71 (EV71), where the compounds each exhibited IC₅₀ (concentration that can inhibit the virus activity by 50%) values of 30.1 μM, 50 μM, and 40.3 μM compared to the positive control ribavirin, which had an IC₅₀ value of 0.60 μM. All the compounds that exhibited antiviral activity are xanthone derivatives.

Another compound that exhibited antiviral activity is metachromin A, a sesquiterpene compound isolated from *D. metachromia* [99]. The compound was able to inhibit the Hepatitis B viral production significantly at an EC₅₀ (concentration where 50% of target cells are protected from death due to infection by the virus) value of 0.8 μM and SI (selectivity index) value of 19.6. The antiviral activity of the compound is contributed by the presence of hydroquinone moiety and the presence of double bond at C-5 and C-9 of the compound, which are attributed to the inhibition of the core promoter of the Hepatitis B viral cells and production of the viral particles. The compound also was identified to suppress the viral replication via down-regulation of the promoter activity.

Another two compounds that were found to exhibit antiviral activity against Hepatitis B viral cells were 3,5-dibromo-2-(2,4-dibromophenoxy)-phenol and 3,4,5-tribromo-2-(2,4-dibromophenoxy)-phenol, which belong to the polybrominated diphenyl ethers, isolated from *Dysidea* sp. [116]. Both of these compounds were able to inhibit the production of Hepatitis B viral cells in the cell line HepG2.2.15.7 in a dose-dependent manner, with an EC₅₀ value of 0.23 μM for 3,5-dibromo-2-(2,4-dibromophenoxy)-phenol and 0.80 μM for 3,4,5-tribromo-2-(2,4-dibromophenoxy)-phenol and SI values of 18.2 and 12.8, respectively. However, both the compounds were found to be more toxic compared to the control entecavir.

Other than Hepatitis B virus, the compound manoalide, which was first isolated from marine sponge *L. variabilis*, exhibited antiviral activity against Hepatitis C virus [117]. The compound was found to inhibit the RNA helicase and ATPase activities of the NS3 protein of Hepatitis C virus in a dose-dependent manner, with IC₅₀ concentrations of 15 μM and 70 μM, respectively. The compound was found to act as a non-competitive inhibitor by inhibiting the NS3 protein from binding to the single-stranded RNA. NS3 is a non-structural protein that involves the coordination of the intracellular process of the Hepatitis C viral particle [118]. Another compound that exhibited antiviral activity against Hepatitis C virus is the compound psammaphin A, a biphenolic bromotyrosine-derived compound [119]. The compound is commonly isolated from marine sponge *Psammaphysilla* (Keller, 1889) sp., *Poecillastra* (Sollas, 1888) sp. and *Jaspis* (Gray, 1867) sp. Similar to the compound manoalide, psammaphin A also exhibits antiviral activity by inhibiting the NS3 protein from binding to the ssRNA in a dose-dependent manner. The compound acts as a non-competitive inhibitor on the helicase motif by binding to the allosteric site, thus modulating ATPase and RNA binding activity via conformational changes of the helicase. The compound also was able to inhibit the viral replication of Hepatitis C at EC₅₀ values of 6.1 and 6.3 μM in subgenomic replicon cells [119]. Thus, the compound, similar to manoalide, exhibited the ability to inhibit ATPase, RNA binding and helicase activity of NS3.

Herpes simplex virus type-1 (HSV-1) is a causative agent of skin infection that results in mucocutaneous lesions known as herpes labialis. The compound manzamine A, a β-carboline alkaloid, which is commonly found in marine sponges genus *Haliclona*, *Chalinidae* (Gray, 1867), *Niphatidae* (van Soest, 1980), *Petrosidae* (Boury-Esnault and van Beveren, 1982), *Thorectidae* (Bergquist, 1978) and *Irciniidae* (Gray, 1867) family [120,121]. The compound manzamine A, which was extracted from marine sponge genus *Acanthostrongylophora* (Hooper, 1984), exhibited antiviral activity against HSV-1 by inhibiting the replication of

the viral particle in a corneal cell line (SIRC) at a concentration as low as 1 μM and an IC_{50} value of 5.6 μM [122]. Manzamine A at the concentration of 1 μM was shown to be able to reduce the plaque formation by 1011-fold. The compound was found to result in down-regulation of the gene ICP0, which is an infectious cellular protein 0 that is produced in the early stage of infection after entering the host cells.

Various compounds isolated from marine sponges have exhibited varying degrees of potency towards HIV. The compounds baculiferins C, E–H, and K–N, amino acid DOPA (2-amino-3-(3',4'-dihydroxyphenyl) propionic acid)-derived alkaloids from marine sponge *Iotrochota baculifera* (Ridley, 1884), and the compounds stelletapeptins A and B, depsipeptide compounds isolated from marine sponge *Stelletta* sp. (Schmidt, 1862), have exhibited potent activity against HIV viral particles [123,124]. The compounds baculiferins C, E–H and K–N were potent against the cell lines MT4 and MAGI cells encoded with HIV-1 IIIB virus. The IC_{50} values of these compounds for both the cell lines range from 0.1 $\mu\text{g}/\text{mL}$ to 8.4 $\mu\text{g}/\text{mL}$ [123]. The compounds stelletapeptines A and B showcased EC_{50} values of 23 nM and 27 nM, respectively, against the human T-cell line CEM-SS, infected with HIV-1RF [124].

4.3. Antifungal Activity

C. albicans is the fungal species that is the frequent causative agent of candidiasis. It has been estimated that human fungal diseases result in the death of more than 1.6 million people every year [125]. Hence, it is necessary to discover new antifungal compounds to ensure these diseases can be treated. There are few compounds extracted from marine sponges that are known to exhibit antifungal activity [126].

Xestodecalactones A, B and C are compounds that have been isolated from the marine sponge *Xestospongia exigua* from Bali Sea, Indonesia [102]. The compound was synthesized by the fungus *Penicillium* cf. *montanense*, which formed a symbiotic interaction with the marine sponge. The compound xestodecalactone B was able to inhibit the growth of *C. albicans* at concentrations of 20 μM or higher.

Another example of compounds with antifungal activity is nortetillapyrone, a tetrahydrofurylhydroxypyran-2-one from the marine sponge *Haliclona cymaeformis* (Esper, 1806). It exhibited antifungal activity against various fungal strains [127,128]. The compound exhibited moderate activity against fungal strains *C. tropicalis* with an MIC value of 250 $\mu\text{g}/\text{mL}$, good activity against *C. glabata*, *Microsporium camis*, and *C. neoformans* at an MIC of 31.25 $\mu\text{g}/\text{mL}$ and against *C. dubliniensis*, and *Trichophyton rubrum* at an MIC value of 62.5 $\mu\text{g}/\text{mL}$. The compound woodylides A and C, a linear polyketide from marine sponge *Plakortis simplex* (Schulze, 1880), was found to exhibit moderate antifungal activity against the fungal strain *C. neoformans*, with IC_{50} concentrations of 3.67 $\mu\text{g}/\text{mL}$ and 10.85 $\mu\text{g}/\text{mL}$, respectively [129]. Both the compounds are categorized as acyclic diol analogues of cyclic polyketide peroxides.

The compounds theonellamide G, a bicyclic glycopeptide, and swinholide I and hurghadolide A macrolides, are isolated from marine sponge *T. swinhoei*. The compounds were found to exhibit significant antifungal activity against the fungal strain *C. albicans* wild strain, an amphotericin-B resistant strain where the compound theonellamide G showcased an activity with IC_{50} values of 4.49 μM and 2.0 μM , respectively. The compound swinholide I showcased moderate inhibitory activity against *C. albicans* wild strain with an MIC of 62.2 $\mu\text{g}/\text{mL}$, whereas amphotericin-B resistant strain exhibited activity at 500 $\mu\text{g}/\text{mL}$, and the compound hurghadolide A exhibited potent activity against both the strains with an MIC value of 31.3 $\mu\text{g}/\text{mL}$ [130,131].

Other compounds extracted from *T. swinhoei* that have exhibited antifungal activity are aurantosides G and I, which are tetramic acid glycosides. The compound aurantoside G exhibited poor activity against *Fusarium solani* with an MIC concentration of 16 $\mu\text{g}/\text{mL}$ but moderate activity against the fungal strains *C. albicans*, and *C. glabrata* with an MIC concentration of 4 $\mu\text{g}/\text{mL}$ and against *C. parapsiopsis* and *C. tropicalis* with an MIC concentration of 2 $\mu\text{g}/\text{mL}$ [132]. The compound aurantoside I exhibited significant antifungal activity

against *C. albicans* and *C. tropicalis* at 0.25 µg/mL; *C. parapsiolsis* at 0.50 µg/mL; *C. glabrata* with an MIC concentration of 0.125 µg/mL; and *F. solani* with an MIC concentration of 1 µg/mL [132].

4.4. Antiparasite Activity

It is interesting to note that marine sponge compounds also display good anti-malarial activity. Meroterpenes, alisiaquinone A, alisiaquinone B, alisiaquinone C and alisiaquinol isolated from New Caledonian deep-sea sponge aqueous ethanol extract have been shown to exhibit anti-malarial activity against enzymes plasmodium kinase Pfnek-1 and protein farnesyltransferase, which can be used as inhibitors to treat malaria [103]. These compounds also exhibited anti-malarial activity against chloroquinone-resistant *Plasmodium falciparum* strain, which demonstrated the potential of the usage of these compounds in malarial resistance. Similarly, sesquiterpenoid compounds isolated from marine sponge *Hyrtios erectus* (Keller, 1889) from Chuuk Island, Federated States of Micronesia, exhibited anti-malarial activity against chloroquinone-resistant Dd2 strain *P. falciparum* [133]. The compound pelorol exhibited strong anti-malarial activity at a concentration of 0.80 µM against *P. falciparum*, whereas compounds smenotronic acid and limaquinone exhibited moderate activity against the strain at 3.51 µM and 2.11 µM, respectively.

Marine sponge compounds have been identified to have antiparasitic activity against parasites *Leishmania*, which causes Leishmaniasis, and *T. cruzi*, which causes Chagas disease, along with anti-malarial activity. Three compounds extracted from marine sponge *V. rigida*—11-hydroxyaerolithionin, purealidin B and aeroplysinin-A—exhibited leishmanicidal activity, anti-malarial activity and anti-chagas activity, respectively [104]. These compounds are bromotyrosine compounds, and the various bioactivities of these compounds are due to the presence of a cyanide group that is very reactive. The cyanide group present in the compound acts as an inhibitor of cytochrome C oxidase enzyme, preventing electron transports that produce ATP, resulting in cell apoptosis [104].

5. Applications in Aquaculture

In recent years, the aquaculture industry has rapidly increased globally. The major limitation in the aquaculture industry is the occurrence and spread of diseases in fishes; this affects the production rate, incurring a huge financial loss [134]. It has been estimated that the aquaculture industry faces a total loss of more than US \$6 billion per year due to frequent outbreaks of diseases primarily caused by bacterial, viral, fungal and/or parasitic attacks [135]. The most common diseases of freshwater and marine fish are *Aeromonas* sp., *Vibrio* sp. and *Streptococcus* sp. [136,137]. The discovery of bioactive compounds from marine sponges and their use as drugs may help in disease management in the aquaculture industry [138].

Marine sponges such as *A. donnani*, *Acanthella elongata* (Dendy, 1905), *Echinodictyum gorgonoides* (Dendy, 1916), *Callyspongia subarmigera* (Ridley, 1884) and *C. diffusa* (Ridley, 1884) have been reported to be highly effective in antibacterial activity. The compounds isolated from crude extracts of marine sponges were capable of controlling the pathogens of fish and shrimp, especially *Aeromonas hydrophila*, *P. aeruginosa*, *V. alginolyticus*, *V. fischeri*, *V. vulnificus*, *V. pelagius*, *V. fluviialis* and *V. anguillarum* [138].

Symbionts such as bacteria and archaea synthesize bioactive compounds, which are utilized by the sponges as natural defense mechanisms for survival [139]. For example, the *Bacillus* strains isolated from marine sponges *Hyrtios* sp., *Verongula* sp. and *Smenospongia* sp. have antibacterial activity against fish pathogens that cause vibriosis, such as *V. harveyi*, *V. parahaemolyticus* and *V. vulnificus* [140].

Sponges are rich in various chemical derivatives, mimicking potent natural biocides in the development of natural product antifoulants (NPA). The rapid expansion of the aquaculture industry requires various drugs, especially antifoulants, to inhibit the growth of unwanted microorganisms (such as barnacles) in aquaculture facilities. A study conducted on the marine sponge *Topsentia ophiraphidites* (Laubenfels, 1934) reported that the

extracts of this sponge have chemical properties that could be used as bioactive components in antifouling paint [141]. Table 4 lists several compounds extracted from marine sponges that are beneficial to the aquaculture industry.

Table 4. Marine sponge species and their application in the aquaculture industry.

Bioactivity	Marine Sponge	Compound	Application	Reference
Antibacterial	<i>Acanthella kletra</i> (Pulitzer-Finali, 1982)	• Axisonitrile-3	• Antibacterial activity against <i>Vibrio harveyi</i> at concentration 250 µg/mL.	[142]
	<i>Callyspongia diffusa</i> (Ridley, 1884)	• 9,12-Octadecadienoic acid	• Moderate antibacterial activity against <i>Vibrio fluvialis</i> , <i>V. harveyi</i> and <i>Vibrio vulnificus</i> . • Potent activity against <i>Vibrio anguillarum</i> .	[143]
	<i>Hexadella</i> sp. (Topsent, 1896)	• 11- <i>N</i> -methyl-moloka'iamine • 11- <i>N</i> -cyano-11- <i>N</i> -methylmoloka'iamine • Kuchinoenamine	• Moderate activity against <i>Aeromonas hydrophila</i> at concentration 100 µg/diameter 6.5 mm disk.	[144]
	<i>Streptomyces tirandamycinicus</i> from unknown sponge, coast of Wenchang City, Hainan Province of China	• Tirandamycin A and B	• Both tirandamycin A and B exhibit potent antibacterial activity against <i>Streptococcus agalactiae</i> HNe0 at MIC values of 2.52 and 2.55 µg/mL, respectively.	[145]
Antifungal	<i>Negombota magnifica</i> (Keller, 1889)	• Latrunculin B	• Potent activity against fish fungal pathogens <i>Exophiala salmonis</i> , <i>Branchiomyces demigrans</i> and <i>Saprolegnia</i> sp.	[146]
Antiviral	<i>Callyspongia</i> sp.	• Polyhydroxy isocopalane	• Strong antiviral activity against white spot syndrome virus (WSSV) at concentration 60 mg/L.	[147]
Antifouling	<i>Acanthella cavernosa</i> (Dendy, 1922)	• Kalihones A, E, O-T • 10- <i>epi</i> -kalihinol X,I • 10β-formamido-kalihinool-A • 10β-formamido-5β-isothiocyanato-kalihinool-A	• Inhibited the larvae settlement of <i>Balanus amphitrite</i> .	[148]
	<i>Agelas</i> sp. (Duchassaing and Michelotti, 1864)	• Agelasine D	• Prevented the settlement of larvae <i>Balanus improvises</i> . • The inhibition was dose-dependent manner, ranging from concentration 0.024 µM to 24 µM.	[149]
	<i>Cymbastela hooperi</i> van Soest (Desqueyroux-Faúndez, Wright and König, 1996)	• Diterpene isonitrile	• Inhibit the settlement of the diatom <i>Nitzschia closterium</i> at concentration 10 µg/mL.	[142]

Table 4. Cont.

Bioactivity	Marine Sponge	Compound	Application	Reference
	<i>Haliclona</i> sp.	<ul style="list-style-type: none"> • Poly 3-alkylpyridinium salt • Saraine-1 • Haminol-2 • Haminol-4 	<ul style="list-style-type: none"> • Poly-3 alkylpyridinium salt was potent to inhibit the settlement of the <i>Amphibalanus</i> (<i>Balanus</i>) <i>amphitrite</i> at EC₅₀ 0.19 µg/mL. • Saraine-1 and haminol-2 equally potent in inhibiting the settlement of the larvae of <i>A. amphitrite</i> with an EC₅₀ of 0.53 and 0.28 µg/mL, respectively. • Haminol-2 and haminol-4 completely inhibited the settlement at the concentration of 10 µg/mL. 	[150]
	<i>Ircinia oros</i> (Schmidt, 1864)	<ul style="list-style-type: none"> • Mixture of Ircinin I • Ircinin II 	<ul style="list-style-type: none"> • Anti-feedant activity against predator fish <i>Thalassoma pavo</i>. 0% pellets with the mixture consumed by the fishes. • Showcased potent inhibition towards the macroalgae <i>Enteromorpha intestinalisi</i>, <i>Ulva lactuca</i> and <i>Sargassum muticum</i>. 	[151]
	<i>Ircinia spinosula</i> (Schmidt, 1862)	<ul style="list-style-type: none"> • Hydroquinone-A • Hydroquinone-B 	<ul style="list-style-type: none"> • Hydroquinone-A exhibited moderate inhibition on <i>E. intestinalis</i> macroalgae and strong inhibition on <i>U. lactuca</i> and <i>S. muticum</i> macroalgae. • Hydroquinone-B showcased poor anti-settlement activity on all three macroalgae. 	[151]
	<i>Ircinia variabilis</i> (Schmidt, 1862)	<ul style="list-style-type: none"> • Variabilin 	<ul style="list-style-type: none"> • Anti-feedant activity against predator fish <i>T. pavo</i>. 5% pellets with the mixture consumed by the fishes. 	[151]
	<i>Xestospongia testudinaria</i> (Lamarck, 1815)	<ul style="list-style-type: none"> • Aragusterol B • 21-O-octadecanoyl-xestokerol A 	<ul style="list-style-type: none"> • The compounds exhibited potent anti-adhesion on biofilm against <i>Pseudoalteromonas</i> sp. D41 and TC8 and <i>Polaribacter</i> sp. TC5. • Aragusterol-B exhibited EC₅₀ values of 23, 20 and 60 µM on <i>Pseudoalteromonas</i> sp. D41, TC8 and <i>Polaribacter</i> sp. TC5, respectively. • 21-O-octadecanoyl-xestokerol A had EC₅₀ values of 25, 10 and 36 µM on <i>Pseudoalteromonas</i> sp. D41, TC8 and <i>Polaribacter</i> sp. TC5, respectively. 	[152]

5.1. Antimicrobial Activity Against Fish Pathogens

Compounds from marine sponges have shown to exhibit various antimicrobial activities, such as antibacterial, antiviral and antifungal properties against various fish pathogens, similar to human pathogens.

5.1.1. Antibacterial

An example of a compound that has exhibited antibacterial activity against fish pathogens is long-chain fatty acid 9,12-Octadecadienoic acid, which was extracted from marine sponge *C. diffusa* (Ridley, 1884) from the Southwest coast of India [143]. The compound was isolated from the methanol extract of the sponge, and 30 µL of the extract was tested for potency against various fish pathogens. The extract exhibited moderate antibacterial activity against fish pathogens *V. fluvialis*, *V. harveyi* and *V. vulnificus* by exhibiting 8 mm, 7 mm and 8 mm zones of inhibition (diameter), respectively. The compound showcased potent antibacterial activity against *V. anguillarum*, with a 12 mm zone of inhibition [143].

Other examples of compounds that exhibited antibacterial activity are the compound sesquiterpene axisonitrile-3, isolated from sponge *A. klettra* (Pulitzer-Finali, 1982), and diterpene isonitrile, isolated from marine sponge *C. hooperi* van Soest (Desqueyroux-Faundez, Wright and König, 1996) [143]. Both compounds exhibited significant antibacterial activity against *V. harveyi*; the compound diterpene isonitrile was significantly potent at concentration 2.5 µg/mL, whereas axisonitrile-3 activity was observed at the concentration 250 µg/mL.

S. tirandamycinicus is an actinobacterium that co-exists with a marine sponge located on the coast of Wenchang City, Hainan Province, China. It synthesizes compounds tirandamycin A and B [145]. Both the compounds showcased potent inhibitory activity against *S. agalactiae* HNe0 strain, with MIC values of 2.52 and 2.55 µg/mL, respectively. The compounds contain a bicyclic ketal and dienoyl tetramic acid moiety. The compounds were found to be able to inhibit RNA polymerase of bacteria and also found to be a specific inhibitor of the futasolone pathway, which is responsible for the synthesis of menaquinone, a crucial component in the electron-transfer system of prokaryotes [153,154].

Three bromotyrosine compounds 11-*N*-methylmoloaliamine, 11-*N*-cyano-11-*N*-methylmoloaliamine, and kuchinoenamine are isolated from marine sponge *Hexadella* sp. [144]. The compounds were found to exhibit moderate antibacterial activity against *A. hydrophila*, a fish pathogen, at a concentration of 100 µg/diameter 6.5 mm disk. The compounds 11-*N*-methylmoloaliamine, 11-*N*-cyano-11-*N*-methylmoloaliamine and kuchinoenamine showcased zones of inhibition with a diameter of 7.5 mm, 8 mm and 7 mm, respectively.

Poly-β-hydroxybutyric acid (PHB), a polymer synthesized by bacteria *Brevibacterium casei* MS104, found to co-exist on the marine sponge *Dendrilla nigra* (Dendy, 1889), was found to exhibit anti-biofilm activity [155]. The compound was found to be able to inhibit the formation of biofilm against shrimp pathogens such as *V. harveyi*, *V. alginolyticus*, *V. vulnificus*, *V. fischeri* and *V. parahaemolyticus* at a concentration of 600 µg. The compound effectively reduced anti-adhesive activity by 96% against *V. vulnificus* and *V. fischeri*, followed by 92% inhibition for *V. parahaemolyticus* and *V. alginolyticus*, and 88% inhibition against *V. harveyi*. The compound PHB is one of the derivatives of the polymer poly-hydroxy alkanates.

Aspergillus sp. LS116 strain, which is found on the marine sponge *Haliclona* sp., was discovered to synthesize the compounds aspergillsteroid A and neocyclocitrinol B, both belonging to steroids with bicyclo A/B rings in their structure [156]. The compound aspergillsteroid A was found to have potent antibacterial activity against *V. harveyi* KP635244 strain at a concentration of 128 µg/mL, with the growth of the bacteria inhibited, whereas the compound neocyclocitrinol B showcased a weak activity at the same concentration against the bacterial strain. Despite belonging to the same group of classification, the difference in the antibacterial activity between the two compounds is attributed to the absence of C-23 hydroxyl branch moiety in the compound aspergillsteroid A [156].

5.1.2. Antifungal and Antiviral

The compound latrunculin B was isolated from the marine sponge *N. magnifica* (Keller, 1889) from Hurghada, Red Sea; it exhibited antifungal activity against fish fungal pathogens *E. salmonis*, *B. demigrans* and *Saprolegnia* sp. [146]. The compound latrunculin B structure

was identified to contain macrolide 1,3, which are fused with a tetrahydro-puran, which contains a side chain 2-thiazolidinone [146]. The compound exhibited potent antifungal properties against *E. salmonis*, *B. demigrans* and *Saprolegnia* sp. by having very low MIC values of 1.50 µg/mL, 0.75 µg/mL and 3.0 µg/mL, respectively. The compound was also identified to be non-toxic towards shrimp [146,157].

An example of a viral diseases that affects the aquaculture industry of shrimp farming is white spot syndrome virus (WSSV), which causes 100% mortality among infected shrimps within 2 to 10 days [158]. The compound polyhydroxy isocopalane, a terpene, was extracted from marine sponge *Callyspongia* sp. in Indonesia [147]. The compound was found to exhibit strong antiviral activity against the WSSV at a concentration of 60 mg/L and resulted in 34% survival of the WSSV infected *Litopenaeus vannamei*. The presence of –OH group in the terpene was found to be responsible for inhibiting the replication of the virus in the host organism cell [147].

5.2. Antifouling Activity

Biofouling is one of the major issues affecting the aquaculture industry. It is the settling and development of unwanted aquatic species such as plants, microorganisms or small animals on the surface, resulting in plagues in various aquaculture organisms, such as shellfish and seaweed [159]. The costs associated with management of biofouling in the aquaculture industry are estimated to be 5–10% of production costs, and the approaches to the management of biofouling vary between location, species, and company [159].

Marine sponges have proved to contain various compounds that exhibit antifouling activities. One such example is the compound baretin (cyclo[(6-bromo-8-tryptophan)arginine]) as well as 8,9-dihydrobaretin (cyclo[(6-bromotryptophan)arginine]) from marine sponge *Geodia barretti* (Bowerbank, 1858) [160]. Both these compounds, isolated from *G. barretti*, belong to the brominated cyclopeptide class. Both compounds have exhibited the ability to inhibit the cyprid larvae of barnacle *B. improvisus*; however, the activity was found to be reversible. The compounds baretin and 8,9-dihydrobaretin were able to inhibit the settlement of the larvae completely at concentrations of 1.9 µM and 19 µM, respectively, in a dose-dependent manner. However, the inhibition by both compounds was found to be reversible when the larvae were transferred from the water with the compounds to freshwater. Both the compounds contain tryptophan, which results in the hydrophobic element, which enables penetration of the compounds into the cell wall and tissues of the larvae [160].

Similarly, the compound agelasine D, extracted from marine sponges of genus *Agelas* (Duchassaing and Michelotti, 1864), also exhibited an inhibitory effect on the settlement of the larvae *B. improvisus* [149]. The compound agelasine D is a 7,9-dialkylpurinium salt with a diterpenoid as a side chain; it inhibited the settlement of the larvae in a dose-dependent manner. The compound inhibited the settlement of the larvae ranging in concentration from 0.024 µM to 24 µM; at concentration 0.24 µM, significant inhibition was observed. However, the compound did not result in the mortality of the larvae at the tested concentration of the compound. The compound agelasine D, from marine sponge *Agelas nakamura* (Hoshino, 1985), also exhibited a similar result, inhibiting the settlement of *B. improvisus* larvae [161].

The diterpenoid compounds kalihinols A, E, O–T, 10-*epi*-kalihinol X,I, 10β-formamido-kalihinoal-A, and 10β-formamido-5β-isothiocyanatokalihinool-A, which were isolated from *A. cavernosa* (Dendy, 1922), exhibited significant antifouling activity against the larvae of barnacle *B. amphitrite* at an EC₅₀ (concentration that inhibits 50% of the larvae settlement in comparison with the control) of 1.85, 0.92, 1.43, 0.72, 1.48, 1.16, 0.53, 0.74, 0.69, 0.37, 1.37 and 0.41 µM, respectively [148]. These compounds are identified to contain a trans-decalin ring carrying a tetrahydrofuran or a tetrahydropyron ring.

Compounds diterpene isonitrile, isolated from marine sponge *C. hooperi*, and axisonitrile-3 from marine sponge *A. kletra* showcased the ability to inhibit the settlement of the diatom *Nitzschia closterium* at concentrations of 10 and 100 µg/mL, respectively [142]. The study found that the compound axisonitrile-3 was more significantly potent in reducing the

settlement of the diatoms. Marine sponge *D. avara* synthesizes compounds such as avarol, a sesquiterpene hydroquinone, and compound avarone, an oxidized avarol quinone that is able to inhibit the settlement of the *B. amphitrite* at both the nauplii and cyprid stage [162]. Both the compounds avarone and avarol were able to inhibit the settlement of the cyprid and were also found to be toxic, resulting to 50% mortality compared to the control at concentrations as low as 13.28 µg/mL and 27.12 µg/mL, respectively. The compound toxicity (resulting mortality) towards the nauplii of the *B. amphitrite* was found to be lower for both the compounds: 1.58 µg/mL for avarol and 25.12 µg/mL for avarone [162].

Three sesterterpene compounds, 7*E*,12*E*,20*Z*-variabilin, cavernosolide, and linternolide A, were extracted from marine sponge *Semitaspongia bactriana* (Cook and Bergquist, 2000) and found to have antifouling activity against the diatom *N. closterium* and bryozoan *Bugula neritina* [163]. The compound 7*E*,12*E*,20*Z*-variabilin was found to be the most toxic towards the diatom *N. closterium*, with an EC₅₀ concentration of 3.52 µM, whereas the compounds cavernosolide and linternolide-A were less potent against the diatom with EC₅₀ values of 5.24 µM and 6.72 µM, respectively. The compounds cavernosolide and linternolide-A were found to be more potent compared to the 7*E*,12*E*,20*Z*-variabilin towards the *B. neritina*, with EC₅₀ values of 1.22 µM, 1.59 µM and 7.41 µM, respectively [163]. The cytotoxic property of the compound 7*E*,12*E*,20*Z*-variabilin is attributed to the presence of tetronic acid moiety, whereas for the compounds cavernosolide and linternolide-A, the presence of γ-hydroxybutenolide moiety contributes to the antifouling activity.

Other examples of compounds that exhibited antifouling activity against *B. amphitrite* cyprids are compounds ircinin I & II mixture and ircinin I and II mixture acetates from the sponge *Ircinia oros* (Schmidt, 1864); hydroquinone-A acetate and hydroquinone-C acetate from sponge *Ircinia spinosula* (Schmidt, 1862); furodysin, euryfuran and 7-deacetoxyolepupane from *Dysidea* sp.; and compound dihydrofurospongine-II from sponge *Cacospongia scalaris* (Schmidt, 1862) [164]. The compounds ircinin I & II mixture, ircinin I and II acetates mixture, furodysin and 7-deacetoxyolepupane were found to be able to inhibit the settlement of the *B. amphitrite*; however, the compounds were found to be toxic, with an LC₅₀ (concentration of compounds resulting in 50% mortality) value of 4.7 ppm, 4.9 ppm, 18.1 ppm and 106.2 ppm, respectively. On the other hand, the compounds euryfuran, hydroquinone-A acetate, dihydrofurospongine II and hydroquinone-C acetate were found to be non-toxic and were able to prevent the settlement of the cyprids in a dose-dependent manner. The compounds euryfuran, hydroquinone-A acetate and dihydroquinone-C acetate at a concentration of 100 µg/mL reduced the settlement of the cyprids to 24.7%, 19.9% and 11.2%, respectively. The presence of furan ring in these compounds was found to have exhibited strong settlement inhibition [164].

6. Applications in Veterinary Commodities

The benefits of the sponges' secondary metabolites are not only useful in aquaculture but also have been extended for use in other veterinary commodities to treat various diseases affecting animals, which will be discussed in this section. Table 5 summarizes the application of the marine sponge compounds among veterinary commodities. A few applications from the marine sponge compounds will be discussed in this section.

Table 5. Summary of marine sponge extracts and compounds with bioactivity for veterinary commodities.

Marine Sponge	Compound	Applications	References
<i>Aplysina thiona</i> (Laubenfels, 1930)	<ul style="list-style-type: none"> Fistularin 3 11-ketofistularin 3 	<ul style="list-style-type: none"> Inhibition of feline leukemia virus with an ED₅₀ 22 µM for Fistularin 3 and 11-ketofistularin 3 at 42 µM. 	[165]
<i>Axinella</i> sp. (Schmidt, 1862)	<ul style="list-style-type: none"> Halichondrin B 	<ul style="list-style-type: none"> Displayed antimetabolic activity as it is capable of binding to bovine tubulin and inhibited microtubule assembly in vitro. 	[166]
<i>Cinachyrella</i> sp. (Wilson, 1925), <i>Haliclona</i> sp., and <i>Petromica citrine</i> (Muricy, Hajdu, Minervino, Madeira and Peixinho, 2001)	<ul style="list-style-type: none"> Aqueous extract 	<ul style="list-style-type: none"> Showcased antibacterial activity against mastitis-causing Coagulase-negative <i>Staphylococci</i>. 	[167]
<i>Monanchora</i> sp. (Carter, 1883)	<ul style="list-style-type: none"> NOR-Batzelladine L 	<ul style="list-style-type: none"> Antiviral activity against avian metapneumovirus due to the presence of compound NOR-Batzelladine L. 	[168,169]
<i>Phoriospongia</i> sp. (Marshall, 1880)	<ul style="list-style-type: none"> Phorioadenine A 	<ul style="list-style-type: none"> Antiparasitic effect against <i>Haemonchus contortus</i> larval development, an important nematode parasite of the ruminant industry. 	[170]
<i>Plakortis halichondrioides</i> (Wilson, 1902)	<ul style="list-style-type: none"> Plakortides 	<ul style="list-style-type: none"> Positive action in activating Ca²⁺ pumping activity of canine-derived cardiac sarcoplasmic reticulum, leading to cardiac relaxation. 	[171]

NOR-Batzelladine L, an extract isolated from the marine sponge *Monanchora* sp. has been shown to have antiviral activity against the avian metapneumovirus (aMPV) [168,169]. The compound was able to inhibit the virus by 97% during the viral adsorption phase. The compound Batzelladine L is a guanidine derived alkaloid. aMPV is a non-segmented single-stranded RNA virus from the family *Paramyxoviridae* [172]. The virus is highly virulent to avian species such as chickens and turkeys and causes a huge loss to the poultry industry [173]. The virus causes rhinotracheitis among turkeys and causes swollen head syndrome among chickens [173]. The illness rate caused by aMPV among chicken flocks ranges between 30–80%, with a mortality rate among these chickens of approximately 15% [172].

The cattle farming industry faces huge economic losses (e.g., dairy milk is always discarded due to infection) yearly to a disease known as mastitis, caused by Coagulase-negative *Staphylococci* (CNS) such as *S. chromogens*, *S. simulans*, *S. hyicus* and *S. epidermidis* [174]. The extracts of marine sponges from Southern Brazil have been reported to harbor potent antibacterial activity against CNS [167]. Both aqueous and ethanolic crude extracts were obtained from the marine sponges *Cinachyrella* sp., *Haliclona* sp. and *Petromica citrine*, and both crude extracts showcased antibacterial activity. Other studies have shown that about 61.2% of bacterial strains from bovine mastitis were inhibited by at least one extract of marine sponges, such as *Cliona celata* complex, *Dragmacidon reticulatum*, *Geodia corticostylifera*, *Guitarra sepia*, *Haliclona* sp. and *Hymeniacion heliophila*.

Feline leukemia virus (FeLV) is the most common infectious disease in domestic cats and has been reported to have a direct association with anemia, immunodeficiency, leukemia and lymphoma [175]. The virus may affect the organs and may also cause secondary and/or opportunistic infections [176]. The virus belongs to the family *Retroviridae*, and the pathogenicity is often associated with the insertion of its double-stranded copy of

DNA from the single-stranded RNA into the chromosome of the host cells [177]. Once the viral particle enters the host cells and successfully inserts its genome into the host genome, the viral genes are then transcribed into functional protein products. It may also remain latent for some time [177]. An extract isolated from marine sponge *Aplysinu thiona* from the Bahamas was tested against FeV; the extract showed antiviral properties against the viral particles [165]. Fistularin 3 and 11-ketofistularin 3 compounds, which are a derivation of bromotyrosine in the extract, are found to be responsible for the antiviral activity.

7. New Compounds from Marine Sponges and Associates

In this subsection, we will discuss a few compounds that have been recently identified (from 2018–2021) based on various bioactivities. Table 6 below lists the compounds that have been identified from the marine sponges, their bioactivities and the classification of the compounds.

Table 6. List of compounds with positive bioactivity discovered from marine sponges and their associates from 2018 to 2021.

Marine Sponge and Associates	Location	Compound	Classification	Bioactivity	Reference
<i>Acanthostrongylophora ingens</i> (Thiele, 1899)	South Sulawesi, Indonesia	<i>epi</i> -tetrahydrohalicyclamine B and tetrahydrohalicyclamine B, acanthocycloamine A, halicyclamine B chloromethylhalicyclamine B and diketopiperazines.	Alkaloids	Antibacterial activity, reduce the production of amyloid β -42, and antikinase activity.	[178]
<i>Aspergillus sp.</i> , a marine fungus associated with marine sponge (not specified)	Xuwen County, China	Misszrtine A	Alkaloids	Anti-cancer activity against HL-60 and LNCap cells.	[179]
<i>Cacospongia mycofijiensis</i> (Kakou, Crews and Bakus, 1987)	‘Eua, Kingdom of Tonga	Zampanolides B, C and D	Macrolide	Anti-proliferative and anti-mitotic activities with microtubule stabilizing activity.	[180]
<i>Dactylspongia elegans</i> T3 (Thiele, 1899)	North Sulawesi, Indonesia	Nakijiquinone V, illimaquinone, smenospongine and dycioceratin C.	Sesquiterpene aminoquinone, sesquiterpene quinones and sesquiterpene hydroquinone.	Antibacterial activity.	[181]
<i>Dactylspongia elegans</i> T3 (Thiele, 1899)	Yongxing Island in the South China Sea	19-methoxydictyoceratin-A	Sesquiterpene quinones	Anti-cancer activity against the human cancer cell lines DU145, SW1990, Huh7, and PANC-1	[182]
<i>Haliclona gracilis</i> (Miklucho-Maclay, 1870)	Shikotan Island	Gracilosulfates A, B, C, D, E, F and G	Steroid	Anti-tumor activity against human prostate cancer.	[183]
<i>Fascaplysinopsis reticulata</i> (Hentschel, 1912)	Passe Bateau, Mayotte	6-bromo-8,1'-dihydro-isoplysin A and 5,6-dibromo-8,1'-dihydro-isoplysin A	Tryptophan derived alkaloids	Antibacterial activity against <i>Vibrio</i> sp.	[184]

Table 6. Cont.

Marine Sponge and Associates	Location	Compound	Classification	Bioactivity	Reference
<i>Haliclona</i> sp. (Grant, 1836)	Mayotte	Osirisynes G, H and I	Long-chain highly oxygenated polyacetylenes	Enzyme-inhibitory activity against proteasome kinase.	[185]
<i>Monascus</i> sp. (Tiegh, 1884), a marine fungus associated with the marine sponge <i>Clathria frondifera</i> (Bowerbank, 1875)	Gulf of Mannar	Monacolin X	Polyketide	Anti-proliferative and anti-migratory activities against human breast cancer cell lines.	[186]
<i>Mycale</i> aff. <i>nularosette</i> (Hoshino, 1981)	Miyagi, Japan	Mycalolide A, mycalolide B and 38-hydroxymycalolide B	Macrolide	Actin depolymerization resulting in incomplete cytokinesis.	[187,188]
<i>Setosphaeria</i> sp. (Leonard and Suggs, 1974), marine fungus associated with the marine sponge <i>Callyspongia</i> sp. (Duchassaing and Michelotti, 1864)	Xuwen County, China	Botryorhodines I and J	Depsidones	Moderate antifungal activities against the phytopathogenic fungi <i>Colletotrichum asianum</i> and <i>Colletotrichum acutatum</i> .	[189]
<i>Stylissa carteri</i> (Dendy, 1889)	Indonesia		Flavonoid, triterpenoid and steroid	Anti-cancer activity against breast cancer MDA MB 231 cell line.	[190]

S. carteri ethanol extract from Indonesia exhibited anti-cancer activity against breast cancer MDA MB 231 cell lines [190]. From the study, it was identified that the extract contains a mixture of compounds: the major compounds that were present in the extract were 1,2-Benzenediol (Figure 4a), Dibutyl phthalate (Figure 4b) and 9,12-Octadecadienoic acid ethyl ester (Figure 4c). Dibutyl phthalate is generally known as a pollutant and is widely used as a plasticizer in the plastic manufacturing industry. However, the presence of the compound in the extract can be due to the synthesis by the microorganism symbionts of the marine sponge. It was found that the compound dibutyl phthalate is synthesized as secondary metabolites by *Pseudomonas* sp. PB01, *Streptomyces ruber* EKH2 and *Rheinheimera japonica* KMM9513, which are marine bacteria species, and filamentous fungi such as *Penicillium lanosum* PTN121, *Trichoderma asperellum* PTN7 and *Aspergillus niger* PTN42 [191–194]. The extract resulted in the death of the breast cancer cell lines via a dose-dependent manner through apoptosis and also by preventing the migration of the cancerous cells. Dibutyl phthalate has been reported to induce proliferation and invasiveness of breast cancer cells [195].




Figure 4. Chemical structures of (a) 1,2-Benzenediol; (b) Dibutyl phthalate; (c) 9,12-Octadecadienoic acid ethyl ester.

In another marine sponge *D. elegans*, T3 methanol extract from Beach Tahuna Bay, North Sulawesi Province Indonesia, exhibited antibacterial activity towards Gram-positive bacteria *Micrococcus luteus* ATCC 4698 and *Bacillus megaterium* DSM32 [181]. The compounds that exhibited antibacterial activity were identified to be sesquiterpene aminoquinone (nakijiquinone V) (Figure 5a), two sesquiterpene quinones (illimaquinone (Figure 5b), and smenospongine (Figure 5c)) and sesquiterpene hydroquinone (dyctioceratine C) (Figure 5d). The compound nakijiquinone was newly discovered.




Figure 5. Chemical structures of (a) Nakijiquinone V; (b) Illimaquinone; (c) Smenospongine; and (d) Dyctioceratine C.

F. reticulata from Passe Bateau, Mayotte, exhibited antibacterial activity against *Vibrio* sp., which are *Vibrio natrigens* and *Vibrio carchariae* [184]. These bacteria are known for the ability to form biofilm and *V. carchariae* is also a known pathogen that can cause high mortality among fishes. The compounds that exhibit antibacterial activity against *Vibrio* sp. are 6-bromo-8,1'-dihydro-isoplycin A (Figure 6a) and 5,6-dibromo-8,1'-dihydro-isoplycin A (Figure 6b), newly identified compounds. The chemical structures of compounds that were isolated from *F. reticulata* are 6,6'-bis-(debromo)-gelliusine F (Figure 6c), 6-bromo-8,1'-dihydro-isoplycin A and 5,6-dibromo-8,1'-dihydro-isoplycin A.




Figure 6. Chemical structures of (a) 6-bromo-8,1'-dihydro-isoplycin A; (b) 5,6-dibromo-8,1'-dihydro-isoplycin A; (c) 6,6'-bis-(debromo)-gelliusine F; and (d) 19-methoxy-dictyoceratin A.

A new compound, 19-methoxy-dictyoceratin-A (Figure 6d), was identified from the marine sponge *D. elegans* and exhibited anti-cancer properties [182]. The compound was shown to exhibit anti-cancer activity against human cancer cell lines DU145 (prostate cancer cell line), SW1990 (pancreatic cancer cell line), Huh7 (liver cancer cell) and PANC-1 (pancreas cancer cell line).

Apart from the marine sponges, some compounds have been identified from the symbionts that co-exist with marine sponges. One such example would be the symbiont *B. subtilis* NMK17, which is associated with the marine sponge *Clathria frondifera* (Bowerbank, 1875) from the Gulf of Mannar, India. In one study, it was found that the partially purified crude extract from *B. subtilis* exhibited anti-cancer activity against breast cancer cell lines (MCF7, MDA-MB-231 and T47D) in a dose-dependent manner [196]. All three cell lines exhibited a reduction in viability of the cell at a concentration as low as 10 µg/mL. Moreover, the extract also exhibited antibacterial activity against both Gram-positive (*Enterococcus faecalis* ATCC 29212 and *S. aureus* ATCC 25923) and Gram-negative (*P. aeruginosa* ATCC 15,442 and *K. pneumoniae* ATCC 13883) bacteria. These bioactivities of *B. subtilis* are attributed to the presence of secondary metabolites such as fatty acids, lipopeptides, macrolactones, polypeptides, polyketides and isocoumarins [196].

Fungi also co-exist with marine sponges as a symbiont. In a study conducted in Xuwen County, China. *Aspergillus* sp. SCSIO XWS03F03, which co-exists as a symbiont with a marine sponge, exhibited anti-cancer activity against HL-60 (promyelocytic leukemia) and LNCap (lymph node from the prostate) cancer cell lines [179]. The compound responsible for the anti-cancer activity was identified to be Misszrtine A (Figure 7a).




Figure 7. Chemical structures of (a) Misszrtine A; (b) Botryorhodines I; and (c) Botryorhodines J.

Two new compounds belonging to depsidone class were discovered from the fungus *Setosphaeria* sp. SCSIO41009, which co-exists as a symbiont with *Callyspongia* sp., from Xuwen County, China [189]. The compounds Botryorhodines I (Figure 7b) and Botryorhodines J (Figure 7c) were shown to exhibit antifungal activities against phytopathogenic fungi *C. asianum* and *C. acutatum*.

Another example of compounds from marine sponge symbionts that have showcased bioactivity is *Cyanobacteria*, which coexists with *Petrosia ficiformis* (Poiret, 1789) from the Mediterranean region. There were eight strains of *Cyanobacteria* isolated from *P. ficiformis*: *Cyanobium* sp., *Synechococcus* sp., *Pseudabaena* sp., *Leptolyngbya ectocarpi*, *Halomicronema* cf. *metazoicum*, and *Halomicronema metazoicum* [197]. However, only *Pseudabaena* sp. aqueous cell supernatant exhibited apoptosis and inhibitory effects on mitosis on the rat-neuron-like B104 cells, human-neuron-like SH-SY5Y cells and human-epithelial-like (cervical adenocarcinoma) (HeLa) cells.

8. Mode of Action

As mentioned earlier, antimicrobial properties derived from these marine sponges can be utilized in the pharmaceutical industry, which related not only to human diseases, but also applied in many other veterinary areas. Despite various compounds being constantly extracted and identified from the sponges, the understanding of the mode of action of these compounds against the targeted microorganisms is still at the infancy stage. Figure 8 illustrates the possible modes of action of these bioactive compounds against various microorganisms.




Figure 8. Mode of action of compounds isolated from the marine sponge on various microorganisms: (a) inhibition of pathogen from the invading mucosal barrier of the host; (b) inhibition of the fusion of pathogenic cells through neutralization of active sites of the pathogen; (c) quenching of quorum sensing molecules released by the pathogens; and (d) blocking the proliferation of malignant cells.

Quorum sensing is a way bacterial cells communicate with each other by producing and secreting small signaling molecules known as autoinducers. These molecules accumulate in the environment, which increases the concentration of bacterial cell density [198]. Quorum sensing plays a vital role in biofilm formation and virulence factors by producing phospholipase, hemolysin and protease [199].

In contrast, quorum quenching is a process that interferes with the process of quorum sensing. It could be a technique that can be applied as a novel therapeutic method to control the infection of microorganisms. Quorum quenching is achieved via a few strategies, including (a) amide bond hydrolysis, (b) lactone hydrolysis, and (c) modification of the acyl chain [198].

Amide bond hydrolysis involves enzyme AHL acylase during the degradation of N-acyl-homoserine lactone (AHL). The degradation is an irreversible process. AHL will undergo hydrolysis, releasing the compound homoserine lactone and fatty acid. This enzymatic activity has been identified in the acyl chain completed by the enzymes AHL oxidase and reductase [200]. These are prokaryotic and eukaryotic cells, whereby the AHL-acylase are known to be able to hydrolyze long-chain AHLs [200,201]. Lactone hydrolysis is an enzymatic reaction whereby the enzyme AHL lactonase will induce the hydrolysis of the homoserine lactone ring found in the AHL, to generate acyl homoserine [200]. This reaction is similar to pH-mediated lactonolysis; hence, the reaction can be reversed through acidification of the medium. Lactonase activity has been identified in *Bacillus* sp., which co-exists as a symbiont with the marine sponge. Another method that is applied to inhibit quorum sensing is through the modification of a process found only in bacteria. For example, P450 monooxygenase, an AHLase obtained from *B. megaterium*, is known to oxidize fatty acids and N-fatty acyl amino acids.

Marine sponge extracts have also been shown to possess the ability to neutralize the active sites of the pathogen, thus inhibiting the fusion of the pathogenic cells to the host cells. For example, an extract obtained from the marine sponge *Siliquariaspongia mirabilis*, containing compounds Mirabamide A, C and D and papuamide A, has been shown to inhibit the fusion of HIV-1 virus through a neutralization process [202]. These compounds interact with the glycoproteins found on the envelope of the virus, thus inhibiting the fusion of the virus to the host cells.

The extracts of marine sponges have also been identified to possess anti-cancer and anti-tumor activities. As seen in Figure 8, the extracts are able to prevent the growth of cancerous cells by preventing the proliferation of these malignant cells through apopto-

sis [203,204]. Apoptosis is a physiological mechanism that induces the death of the cells to maintain cellular homeostasis. Some marine sponge extracts may induce apoptosis through an intrinsic pathway. The intrinsic pathway is generally triggered when there is enormous intracellular damage, such as DNA damage, oxidative stress and cytokine withdrawal [205]. Marine sponges such as *Ircinia ramose*, *Monanchora* sp. and *Xestospongia* sp. can induce apoptosis of the cancerous cells by chromatin condensation or DNA fragmentation [205]. Another mechanism to induce apoptosis is based on p53 dependent apoptosis [204]. The genes p21, NOXA, PUMA and Bax are increasingly expressed, and cleaved Caspase-9 and cleaved Caspase-3 also increases, thus resulting in the apoptosis of cancerous cells.

9. Conclusions

With the advancement of technology, many sponge species from the poles to the tropics have been tested for their bioactivities. These compounds and extracts have showcased a wide range of potency, ranging from strong to moderate antimicrobial activity towards various pathogens, including antibiotic-resistant bacteria strains, and viruses such as HIV as well as anti-fouling activities. Despite numerous tests being conducted on human-based pathogens, it is also necessary to focus on fish pathogens, such as WSSV and tilapia lake virus, and fungal strains such as *Ichthyophonus*, which also causes trouble in the aquaculture industry. However, before these compounds can be commercialized for human or animal applications, in-depth investigations need to be conducted on the toxicity of these extracts and compounds on animal cell lines as well as on the mechanism of these compounds that acts on living cells. Most importantly, the metabolites isolated from marine sponges are only available in a very small volume from the sponge extracts. To overcome this issue, it is necessary to identify methods to synthesize these beneficial compounds on large scale for commercial purposes. Furthermore, the compounds obtained from marine sponges need to be further studied to understand their mode of action against various pathogens, thus elucidating the effect of these compounds at the gene and protein level and their efficacy on pathogenic microorganisms. Only through a series of stringent investigations will new and effective drug agents be developed to mitigate current issues and provide favorable outcomes to stakeholders.

Author Contributions: D.V. wrote the manuscript. K.-S.L., C.-M.C., S.-H.E.L. and J.-Y.L. conceptualized the flow and technical aspects of the manuscript. W.-S.Y., K.Y. and R.S. contributed specialized sections. All authors have read and agreed to the published version of the manuscript.

Funding: This study is funded by a grant from the Ministry of Higher Education Malaysia via the Higher Institution Centre of Excellence (HiCoE) under vote No. 6369100. The authors are also grateful to UCSI University Research Excellence & Innovation Grant (REIG-FAS-2020/032) for funding this study.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Sutton, T.T.; Clark, M.R.; Dunn, D.C.; Halpin, P.N.; Rogers, A.D.; Guinotte, J.; Bograd, S.J.; Angel, M.V.; Perez, J.A.A.; Wishner, K.; et al. A global biogeographic classification of the mesopelagic zone. *Deep. Res. Part I Oceanogr. Res. Pap.* **2017**, *126*, 85–102. [[CrossRef](#)]
2. Barzkar, N.; Jahromi, S.T.; Poorsaheli, H.B.; Vianello, F. Metabolites from marine microorganisms, micro, and macroalgae: Immense scope for pharmacology. *Mar. Drugs* **2019**, *17*, 464. [[CrossRef](#)]
3. Ebada, S.S.; Proksch, P. The chemistry of marine sponges. In *Handbook of Marine Natural Products*; Fattorusso, E., Gerwick, W.H., Tagliatela-Scafati, O., Eds.; Springer: Berlin/Heidelberg, Germany, 2012; pp. 191–293, ISBN 9789048138340.
4. Petersen, L.-E.; Kellermann, M.Y.; Schupp, P.J. Secondary metabolites of marine microbes: From natural products chemistry to chemical ecology. In *YOUMARES 9—The Oceans: Our Research, Our Future*; Jungblut, S., Liebich, V., Bode-Dalby, M., Eds.; Springer: Berlin/Heidelberg, Germany, 2019; pp. 159–180, ISBN 9783030203894.

5. Carte, B.K. Marine natural products as a source of novel pharmacological agents. *Curr. Opin. Biotechnol.* **1993**, *4*, 275–279. [[CrossRef](#)]
6. Senthilkumar, K.; Kim, S.K. Marine invertebrate natural products for anti-inflammatory and chronic diseases. *Evid. Based Complement. Altern. Med.* **2013**, *2013*. [[CrossRef](#)] [[PubMed](#)]
7. Jha, R.K.; Zi-rong, X. Biomedical compounds from marine organisms. *Mar. Drugs* **2004**, *2*, 123–146. [[CrossRef](#)]
8. Carson, M.A.; Clarke, S.A. Bioactive Compounds from Marine Organisms: Potential for Bone Growth and Healing. *Mar. Drugs* **2018**, *16*, 340. [[CrossRef](#)] [[PubMed](#)]
9. Kiuru, P.; D’Auria, M.V.; Muller, C.D.; Tammela, P.; Vuorela, H.; Yil-Kauhaluoma, J. Exploring Marine Resources for Bioactive Compounds. *Planta Med.* **2014**, *80*, 1234–1246. [[CrossRef](#)]
10. Pandey, A. Pharmacological Significance of Marine Microbial Bioactive Compounds. *Environ. Chem. Lett.* **2019**, *17*, 1741–1751. [[CrossRef](#)]
11. Laport, M.; Santos, O.; Muricy, G. Marine Sponges: Potential sources of new antimicrobial drugs. *Curr. Pharm. Biotechnol.* **2009**, *10*, 86–105. [[CrossRef](#)]
12. Bell, J.J. The functional roles of marine sponges. *Estuar. Coast. Shelf Sci.* **2008**, *79*, 341–353. [[CrossRef](#)]
13. Gomes, N.G.M.; Dasari, R.; Chandra, S.; Kiss, R.; Kornienko, A. Marine invertebrate metabolites with anticancer activities: Solutions to the “supply problem”. *Mar. Drugs* **2016**, *14*, 98. [[CrossRef](#)] [[PubMed](#)]
14. Food and Agriculture Organization of the United Nations. *Sponges and Their Role in the Marine Environment*; FAO: Rome, Italy, 2017.
15. Blunt, J.W.; Copp, B.R.; Munro, M.H.G.; Northcote, P.T.; Prinsep, M.R. Marine natural products. *Mar. Nat. Prod.* **2004**, *21*, 1–49. [[CrossRef](#)]
16. Cheng, C.; Othman, E.M.; Reimer, A.; Grüne, M.; Kozjak-Pavlovic, V.; Stopper, H.; Hentschel, U.; Abdelmohsen, U.R. Ageloline A, New Antioxidant and Antichlamydia Quinolone from the Marine Sponge-Derived Bacterium *Streptomyces* sp. SBT345. *Tetrahedron Lett.* **2016**, *57*, 2786–2789. [[CrossRef](#)]
17. Cheng, M.M.; Tang, X.L.; Sun, Y.T.; Song, D.Y.; Cheng, Y.J.; Liu, H.; Li, P.L.; Li, G.Q. Biological and chemical diversity of marine sponge-derived microorganisms over the last two decades from 1998 to 2017. *Molecules* **2020**, *25*, 853. [[CrossRef](#)]
18. Loya, S.; Hizi, A. The Inhibition of Human Immunodeficiency Virus Type 1 Reverse Transcriptase by Avarol and Avarone Derivatives. *FEBS Lett.* **1990**, *269*, 131–134. [[CrossRef](#)]
19. Sipkema, D.; Franssen, M.C.R.; Osinga, R.; Tramper, J.; Wijffels, R.H. Marine Sponges as Pharmacy. *Mar. Biotechnol.* **2005**, *7*, 142–162. [[CrossRef](#)]
20. Wellington, K.D.; Cambie, R.C.; Rutledge, P.S.; Bergquist, P.R. Chemistry of sponges. 19. Novel bioactive metabolites from *Hamigera tarangaensis*. *J. Nat. Prod.* **2000**, *63*, 79–85. [[CrossRef](#)]
21. Sagar, S.; Kaur, M.; Minneman, K.P. Antiviral Lead Compounds from Marine Sponges. *Mar. Drugs* **2010**, *8*, 2619–2638. [[CrossRef](#)] [[PubMed](#)]
22. Quévrain, E.; Domart-Coulon, I.; Pernice, M.; Bourguet-Kondracki, M.L. Novel Natural Parabens produced by a Microbulbifer Bacterium in its Calcareous Sponge Host *Leuconia nivea*. *Environ. Microbiol.* **2009**, *11*, 1527–1539. [[CrossRef](#)]
23. Steinert, G.; Stauffer, C.H.; Aas-Valleriani, N.; Borchert, E.; Bhushan, A.; Campbell, A.; De Mares, M.C.; Costa, M.; Gutleben, J.; Knobloch, S.; et al. *BluePharmTrain: Biology and Biotechnology of Marine Sponges*; Springer: Cham, Switzerland, 2018; ISBN 9783319690759.
24. Hentschel, U.; Piel, J.; Degnan, S.M.; Taylor, M.W. Genomic insights into the marine sponge microbiome. *Nat. Rev. Microbiol.* **2012**, *10*, 641–654. [[CrossRef](#)]
25. Wehrli, M.; Steinert, M.; Hentschel, U. Bacterial uptake by the marine sponge *Aplysina aerophoba*. *Microb. Ecol.* **2007**, *53*, 355–365. [[CrossRef](#)]
26. Taylor, M.W.; Hill, R.T.; Hentschel, U. Meeting Report: 1st International Symposium on Sponge Microbiology. *Mar. Biotechnol.* **2011**, *13*, 1057–1061. [[CrossRef](#)]
27. Wilkinson, C.R. Microbial associations in sponges. I. Ecology, physiology and microbial populations of coral reef sponges. *Mar. Biol.* **1978**, *49*, 161–167. [[CrossRef](#)]
28. Wilkinson, C.R. Microbial associations in sponges. II. Numerical analysis of sponge and water bacterial populations. *Mar. Biol.* **1978**, *49*, 169–176. [[CrossRef](#)]
29. Hentschel, U.; Usher, K.M.; Taylor, M.W. Marine sponges as microbial fermenters. *FEMS Microbiol. Ecol.* **2006**, *55*, 167–177. [[CrossRef](#)] [[PubMed](#)]
30. Perdicasis, S.; Vlachogianni, T.; Valavanidis, A. Bioactive natural substances from marine sponges: New developments and prospects for future pharmaceuticals. *Nat. Prod. Chem. Res.* **2013**, *1*, 2–10. [[CrossRef](#)]
31. Thompson, J.E.; Walker, R.P.; Faulkner, D.J. Screening and bioassays for biologically-active substances from forty marine sponge species from San Diego, California, USA. *Mar. Biol.* **1985**, *88*, 11–21. [[CrossRef](#)]
32. Stowe, S.D.; Richards, J.J.; Tucker, A.T.; Thompson, R.; Melander, C.; Cavanagh, J. Anti-biofilm compounds derived from marine sponges. *Mar. Drugs* **2011**, *9*, 2010–2035. [[CrossRef](#)] [[PubMed](#)]
33. Unson, M.D.; Holland, N.D.; Faulkner, D.J. A brominated secondary metabolite synthesized by the cyanobacterial symbiont of a marine sponge and accumulation of the crystalline metabolite in the sponge tissue. *Mar. Biol.* **1994**, *119*, 1–11. [[CrossRef](#)]

34. Piel, J.; Hui, D.; Wen, G.; Butzke, D.; Platzer, M.; Fusetani, N.; Matsunaga, S. Antitumor polyketide biosynthesis by an uncultivated bacterial symbiont of the marine sponge *Theonella swinhoei*. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 16222–16227. [[CrossRef](#)]
35. Unson, M.D.; Faulkner, D.J. Cyanobacterial symbiont biosynthesis of chlorinated metabolites from *Dysidea herbacea* (Porifera). *Experientia* **1993**, *49*, 349–353. [[CrossRef](#)]
36. Andrade, P.; Willoughby, R.; Pomponi, S.A.; Kerr, R.G. Biosynthetic studies of the alkaloid, stevensine, in a cell culture of the marine sponge *Teichaxinella morchella*. *Tetrahedron Lett.* **1999**, *40*, 4775–4778. [[CrossRef](#)]
37. Turon, X.; Becerro, M.A.; Uriz, M.J. Distribution of brominated compounds within the sponge *Aplysina aerophoba*: Coupling of X-ray microanalysis with cryofixation techniques. *Cell Tissue Res.* **2000**, *301*, 311–322. [[CrossRef](#)]
38. Uriz, M.J.; Turon, X.; Galera, J.; Tur, J.M. New light on the cell location of avarol within the sponge *Dysidea avara* (Dendroceratida). *Cell Tissue Res.* **1996**, *285*, 519–527. [[CrossRef](#)]
39. Reintamm, T.; Lopp, A.; Kuuskalu, A.; Pehk, T.; Kelve, M. ATP N-glycosidase: A novel ATP-converting activity from a marine sponge *Axinella polypoides*. *Eur. J. Biochem.* **2003**, *270*, 4122–4132. [[CrossRef](#)] [[PubMed](#)]
40. Litwack, G. Nucleic Acids and Molecular Genetics. In *Human Biochemistry*; Academic Press: Los Angeles, CA, USA, 2018; pp. 257–317, ISBN 9780123838643.
41. He, Q.; Miao, S.; Ni, N.; Man, Y.; Gong, K. A Review of the Secondary Metabolites from the Marine Sponges of the Genus *Aaptos*. *Nat. Prod. Commun.* **2020**, *15*. [[CrossRef](#)]
42. Proksch, P. Defensive Roles for Secondary Metabolites from Marine Sponges and Sponge-feeding Nudibranchs. *Toxicon* **1994**, *32*, 639–655. [[CrossRef](#)]
43. Sperry, S. *Novel Secondary Metabolites from Marine Sponges and Sponge-associated Fungi*; University of California: Santa Cruz, CA, USA, 1998.
44. Gupta, P. Chemical Constituents of *Haliclona*: An Overview. *J. Pharmacogn. Phytochem.* **2019**, *8*, 823–827.
45. Forenza, S.; Minale, L.; Riccio, R.; Fattorusso, E. New Bromo-Pyrrole Derivatives from the Sponge *Agelas oroides*. *J. Chem. Soc. D Chem. Commun.* **1971**, *285*, 1129–1130. [[CrossRef](#)]
46. Nakao, Y.; Kuo, J.; Yoshida, W.Y.; Kelly, M.; Scheuer, P.J. More Kapakahines from the Marine Sponge *Cribrorchalina olemda*. *Org. Lett.* **2003**, *5*, 1387–1390. [[CrossRef](#)]
47. Su, J.Y.; Meng, Y.H.; Zeng, L.M. Stelletin A, A New Triterpenoid Pigment from the Marine Sponge *Stelletta tenuis*. *J. Nat. Prod.* **1994**, *57*, 1450–1451. [[CrossRef](#)]
48. Baldwin, J.E.; Whitehead, R.C. On the Biosynthesis of Manzamines. *Tetrahedron Lett.* **1992**, *33*, 2059–2062. [[CrossRef](#)]
49. Patrick, G.L.; Turner, H. Kinases and Kinase Inhibitors. In *Antimalarial Agents*; Patrick, G.L., Ed.; Elsevier: Amsterdam, The Netherlands, 2020; pp. 459–494, ISBN 9780081012109.
50. de Silva, E.D.; Scheuer, P.J. Monoalide, an Antibiotic Sesterterpenoid from the Marine Sponge *Luffariella variabilis*. *Tetrahedron Lett.* **1980**, *21*, 1611–1614. [[CrossRef](#)]
51. Zhang, Q.W.; Lin, L.G.; Ye, W.C. Techniques for Extraction and Isolation of Natural Products: A Comprehensive Review. *Chin. Med.* **2018**, *13*, 1–26. [[CrossRef](#)] [[PubMed](#)]
52. Getachew, A.T.; Jacobsen, C.; Holdt, S.L. Emerging Technologies for the Extraction of Marine Phenolics: Opportunities and Challenges. *Mar. Drugs* **2020**, *18*, 389. [[CrossRef](#)]
53. Bayona, L.M.; Videnova, M.; Choi, Y.H. Increasing Metabolic Diversity in Marine Sponges Extracts by Controlling Extraction Parameters. *Mar. Drugs* **2018**, *16*, 393. [[CrossRef](#)]
54. Nn, A. A Review on the Extraction Methods Use in Medicinal Plants, Principle, Strength and Limitation. *Med. Aromat. Plants* **2015**, *04*, 3–8.
55. Abubakar, A.R.; Haque, M. Preparation of Medicinal Plants: Basic Extraction and Fractionation Procedures for Experimental Purposes. *J. Pharm. Bioallied Sci.* **2020**, *12*, 1–10. [[CrossRef](#)]
56. Grosso, C.; Valentão, P.; Ferreres, F.; Andrade, P.B. Alternative and Efficient Extraction Methods for Marine-derived Compounds. *Mar. Drugs* **2015**, *13*, 3182–3230. [[CrossRef](#)]
57. Pantidos, N.; Boath, A.; Lund, V.; Conner, S.; McDougall, G.J. Phenolic-rich Extracts from the Edible Seaweed, *Ascophyllum nodosum*, Inhibit α -amylase and α -glucosidase: Potential Anti-hyperglycemic Effects. *J. Funct. Foods* **2014**, *10*, 201–209. [[CrossRef](#)]
58. Lopes, G.; Sousa, C.; Silva, L.R.; Pinto, E.; Andrade, P.B.; Bernado, J.; Mougá, T.; Valentão, P. Can Phlorotannins Purified Extracts Constitute a Novel Pharmacological Alternative for Microbial Infections with Associated Inflammatory Conditions? *PLoS ONE* **2012**, *7*, e31145. [[CrossRef](#)]
59. Catarino, M.D.; Silva, A.M.S.; Mateus, N.; Cardoso, S.M. Optimization of Phlorotannins Extraction from *Fucus vesiculosus* and Evaluation of their Potential to Prevent Metabolic Disorders. *Mar. Drugs* **2019**, *17*, 162. [[CrossRef](#)] [[PubMed](#)]
60. Parys, S.; Kehraus, S.; Krick, A.; Glombitza, K.W.; Carmeli, S.; Klimo, K.; Gerhäuser, C.; König, G.M. In vitro Chemopreventive Potential of Fucophlorethols from the Brown Alga *Fucus vesiculosus* L. by Anti-oxidant Activity and Inhibition of Selected Cytochrome P450 Enzymes. *Phytochemistry* **2010**, *71*, 221–229. [[CrossRef](#)]
61. Rostagno, M.A.; Villares, A.; Guillaumon, E.; García-Lafuente, A.; Martínez, J.A. Sample Preparation for the Analysis of Isoflavones from Soybeans and Soy Foods. *J. Chromatogr. A* **2009**, *1216*, 2–29. [[CrossRef](#)]
62. Christen, P.; Kaufmann, B. Recent Extraction Techniques for Natural Products: Microwave-assisted Extraction and Pressurised Solvent Extraction. *Phytochem. Anal.* **2002**, *113*, 105–113.

63. Luque-García, J.L.; Luque De Castro, M.D. Ultrasound: A Powerful Tool for Leaching. *Trends Anal. Chem.* **2003**, *22*, 41–47. [[CrossRef](#)]
64. Chemat, F.; Khan, M.K. Ultrasonics Sonochemistry Applications of ultrasound in food technology: Processing, preservation and extraction. *Ultrason. Sonochem.* **2011**, *18*, 813–835. [[CrossRef](#)] [[PubMed](#)]
65. Zou, T.B.; Jia, Q.; Li, H.W.; Wang, C.X.; Wu, H.F. Response Surface Methodology for Ultrasound-assisted Extraction of Astaxanthin from *Haematococcus pluvialis*. *Mar. Drugs* **2013**, *11*, 1644–1655. [[CrossRef](#)] [[PubMed](#)]
66. Picó, Y. Ultrasound-assisted Extraction for Food and Environmental Samples. *Trends Anal. Chem.* **2013**, *43*, 84–99. [[CrossRef](#)]
67. Vardanega, R.; Santos, D.T.; De Almeida, M.A. Intensification of Bioactive Compounds Extraction from Medicinal Plants using Ultrasonic Irradiation. *Pharmacogn. Rev.* **2014**, *8*, 88–95. [[PubMed](#)]
68. Wang, L. Advances in Extraction of Plant Products in Nutraceutical Processing. In *Handbook of Nutraceuticals*; CRC Press: Boca Raton, FL, USA, 2011; pp. 15–52.
69. Herrero, M.; Castro-Puyana, M.; Mendiola, J.A.; Ibañez, E. Compressed Fluids for the Extraction of Bioactive Compounds. *Trends Anal. Chem.* **2013**, *43*, 67–83. [[CrossRef](#)]
70. Kadam, S.U.; Tiwari, B.K.; O'Donnell, C.P. Application of Novel Extraction Technologies for Bioactives from Marine Algae. *J. Agric. Food Chem.* **2013**, *61*, 4667–4675. [[CrossRef](#)]
71. Riguera, R. Isolating bioactive compounds from marine organisms. *J. Mar. Biotechnol.* **1997**, *5*, 187–193.
72. Ebada, S.S.; Edrada, R.A.; Lin, W.; Proksch, P. Methods for Isolation, Purification and Structural Elucidation of Bioactive Secondary Metabolites from Marine Invertebrates. *Nat. Protoc.* **2008**, *3*, 1820–1831. [[CrossRef](#)] [[PubMed](#)]
73. Hutagalung, R.A.; Victor; Karjadidjaja, M.; Prasasty, V.D.; Mulyono, N. Extraction and Characterization of Bioactive Compounds from Cultured and Natural Sponge, *Haliclona molitba* and *Stylotella aurantium* Origin of Indonesia. *Int. J. Biosci. Biochem. Bioinform.* **2014**, *4*, 14–18.
74. Bakkali, F.; Averbeck, S.; Averbeck, D.; Idaomar, M. Biological effects of essential oils—A review. *Food Chem. Toxicol.* **2008**, *46*, 446–475. [[CrossRef](#)] [[PubMed](#)]
75. Varijakzhan, D.; Yang, S.-K.; Chong, C.M.; Akseer, R.; Alhosani, M.S.; Thomas, W.; Lai, K.S.; Lim, S.H.E. Essential oils as potential antimicrobial agents. In *Mitigation of Antimicrobial Resistance*; Panwar, H., Sharma, C., Lichtfouse, E., Eds.; Springer: Berlin/Heidelberg, Germany, 2021; pp. 3975–3988.
76. Jiang, Z.; Kempinski, C.; Chappell, J. Extraction and Analysis of Oxysterols. *Curr. Protoc. Plant Biol.* **2016**, *1*, 345–358. [[CrossRef](#)]
77. Selvin, J.; Lipton, A.P. Biopotentials of Secondary Metabolites Isolated from Marine Sponges. *Hydrobiologia* **2004**, *513*, 231–238. [[CrossRef](#)]
78. Ortiz, A.R.; Pisabarro, M.T.; Gago, F. Molecular Model of the Interaction of Bee Venom Phospholipase A2 with Manoalide. *J. Med. Chem.* **1993**, *36*, 1866–1879. [[CrossRef](#)]
79. Jacobson, P.B.; Marshall, L.A.; Sung, A.; Jacobs, R.S. Inactivation of Human Synovial Fluid Phospholipase a2 by the Marine Natural Product, Manoalide. *Biochem. Pharmacol.* **1990**, *39*, 1557–1564. [[CrossRef](#)]
80. McCabe, T.; Clardy, J.; Minale, L.; Pizza, C.; Zollo, F.; Riccio, R. A triterpenoid Pigment with the Isomalabaricane Skeleton from the Marine Sponge *Stelletta* sp. *Tetrahedron Lett.* **1982**, *23*, 3307–3310. [[CrossRef](#)]
81. Ravi, B.N.; Wells, R.J.; Croft, K.D. Malabaricane Triterpenes from a Fijian Collection of the Sponge *Jaspis stellifera*. *J. Org. Chem.* **1981**, *46*, 1998–2001. [[CrossRef](#)]
82. Ang, K.K.H.; Holmes, M.J.; Higa, T.; Hamann, M.T.; Kara, U.A.K. In Vivo Antimalarial Activity of the Beta-Carboline Alkaloid Manzamine, A. *Antimicrob. Agents Chemoth.* **2000**, *44*, 1645–1649. [[CrossRef](#)]
83. Sakai, R.; Higa, T.; Jefford, C.W.; Bernardinelli, G. Manzamine A, a Novel Antitumor Alkaloid from a Sponge. *J. Am. Chem. Soc.* **1986**, *108*, 6404–6405. [[CrossRef](#)]
84. Nakao, Y.; Yeung, B.K.S.; Yoshida, W.Y.; Scheuer, P.J.; Kelly-borges, M. Kapakahine B: A Cyclic Hexapeptide with an α -Carboline Ring system from the Marine Sponge *Cribrochalina olemda*. *J. Am. Chem. Soc.* **1995**, *117*, 8271–8272. [[CrossRef](#)]
85. Yeung, B.K.S.; Nakao, Y.; Kinnel, R.B.; Carney, J.R.; Yoshida, W.Y.; Scheuer, P.J.; Kelly-Borges, M. The Kapakahines, Cyclic Peptides from the Marine Sponge *Cribrochalina olemda*. *J. Org. Chem.* **1996**, *61*, 7168–7173. [[CrossRef](#)]
86. Wang, X.; Yu, H.; Xing, R.; Li, P. Characterization, Preparation, and Purification of Marine Bioactive Peptides. *BioMed Res. Int.* **2017**, *2017*. [[CrossRef](#)]
87. Vitali, A. Antimicrobial Peptides Derived from Marine Sponges. *Am. J. Clin. Microbiol. Antimicrob.* **2018**, *1*, 1006.
88. Matsunaga, S.; Fusetani, N.; Konosu, S. Bioactive Marine Metabolites, IV. Isolation and the Amino Acid Composition of Discodermin A, an Antimicrobial Peptide, from the Marine Sponge *Discodermia kiiensis*. *J. Nat. Prod.* **1985**, *48*, 236–241. [[CrossRef](#)]
89. Matsunaga, S.; Fusetani, N.; Konosu, S. Bioactive Marine Metabolites VI. Structure Elucidation of Discodermin A, an Antimicrobial Peptide from the Marine Sponge *Discodermia kiiensis*. *Tetrahedron Lett.* **1984**, *25*, 5165–5168. [[CrossRef](#)]
90. Negi, B.; Kumar, D.; Rawat, D.S. Marine Peptides as Anticancer Agents: A Remedy To Mankind By Nature. *Curr. Protein Pept. Sci.* **2017**, *18*, 1–20. [[CrossRef](#)]
91. Wang, X.; Morinaka, B.I.; Molinski, T.F. Structures and Solution Conformational Dynamics of Stylissamides G and H from the Bahamian Sponge *Stylissa caribica*. *Nat. Prod.* **2014**, *77*, 625–630. [[CrossRef](#)]
92. Davies, J.; Davies, D. Origins and Evolution of Antibiotic Resistance Julian. *Microbiol. Mol. Biol. Rev.* **2010**, *74*, 417–433. [[CrossRef](#)]

93. Varijakzhan, D.; Chong, C.M.; Abushelaibi, A.; Lai, K.S.; Lim, S.H.E. Middle eastern plant extracts: An alternative to modern medicine problems. *Molecules* **2020**, *25*, 1126. [[CrossRef](#)] [[PubMed](#)]
94. Graça, A.P.; Viana, F.; Bondoso, J.; Correia, M.I.; Gomes, L.; Humanes, M.; Reis, A.; Xavier, J.R.; Gaspar, H.; Lage, O.M. The antimicrobial activity of heterotrophic bacteria isolated from the marine sponge *Erylus deficiens* (Astrophorida, Geodiidae). *Front. Microbiol.* **2015**, *6*, 389. [[PubMed](#)]
95. Sadanandan, R.; Rauf, A.A. Antibacterial activity of a lectin isolated from marine sponge *Axinella donnani*. *J. Aquat. Biol. Fish.* **2018**, *6*, 159–164.
96. Gupta, P.; Sharma, U.; Schulz, T.C.; McLean, A.B.; Robins, A.J.; West, L.M. Bicyclic C21 terpenoids from the marine sponge *Clathria compressa*. *J. Nat. Prod.* **2012**, *75*, 1223–1227. [[CrossRef](#)]
97. Keffer, J.L.; Plaza, A.; Bewley, C.A. Motualevic Acids A-F, Antimicrobial Acids from the Sponge *Siliquariaspongia* sp. *Org. Lett.* **2009**, *11*, 1087–1090. [[CrossRef](#)] [[PubMed](#)]
98. Yu, H.B.; Yang, F.; Sun, F.; Li, J.; Jiao, W.H.; Gan, J.H.; Hu, W.Z.; Lin, H.W. Aaptamine Derivatives with Antifungal and Anti-HIV-1 Activities from the South China Sea Sponge *Aaptos aaptos*. *Mar. Drugs* **2014**, *12*, 6003–6013. [[CrossRef](#)]
99. Yamashita, A.; Tamaki, M.; Kasai, H.; Tanaka, T.; Otoguro, T.; Ryo, A.; Maekawa, S.; Enomoto, N.; De Voogd, N.J.; Tanaka, J.; et al. Inhibitory Effects of Metachromin A on Hepatitis B Virus Production via Impairment of the Viral Promoter Activity. *Antivir. Res.* **2017**, *145*, 136–145. [[CrossRef](#)]
100. Qin, C.; Lin, X.; Lu, X.; Wan, J.; Zhou, X.; Liao, S.; Tu, Z. Sesquiterpenoids and Xanthenes Derivatives Produced by Sponge-Derived Fungus *Stachybotry* sp. HH1. *J. Antibiot.* **2014**, *68*, 121–125. [[CrossRef](#)]
101. Kumar, R.; Subramani, R.; Aalbersberg, W. Three Bioactive Sesquiterpene Quinones from the Fijian Marine Sponge of the Genus *Hippospongia*. *Nat. Prod. Res.* **2013**, *27*, 1488–1491. [[CrossRef](#)] [[PubMed](#)]
102. Karpiński, T.M. marine drugs Marine Macrolides with Antibacterial and/or antifungal activity. *Mar. Drugs* **2019**, *17*, 241. [[CrossRef](#)]
103. Desoubzdanne, D.; Marcourt, L.; Raux, R.; Chevalley, S.; Dorin, D.; Doerig, C.; Valentin, A.; Ausseil, F.; Debitus, C. Alisiaquinones and Alisiaquinol, dual inhibitors of *Plasmodium falciparum* enzyme targets from a new caledonian deep water sponge. *J. Nat. Prod.* **2008**, *71*, 1189–1192. [[CrossRef](#)] [[PubMed](#)]
104. Galeano, E.; Thomas, O.P.; Robledo, S.; Munoz, D.; Martinez, A. Antiparasitic Bromotyrosine Derivatives from the Marine Sponge *Verongula rigida*. *Mar. Drugs* **2011**, *9*, 1902–1913. [[CrossRef](#)] [[PubMed](#)]
105. Nazzaro, F.; Fratianni, F.; De Martino, L.; Coppola, R.; De Feo, V. Effect of essential oils on pathogenic bacteria. *Pharmaceuticals* **2013**, *6*, 1451–1474. [[CrossRef](#)]
106. Moo, C.-L.; Yang, S.-K.; Yusoff, K.; Ajat, M.; Thomas, W.; Abushelaibi, A.; Lim, S.-H.-E.; Lai, K.-S. Mechanisms of antimicrobial resistance (AMR) and alternative approaches to overcome AMR. *Curr. Drug Discov. Technol.* **2019**, *16*, 430–447. [[CrossRef](#)] [[PubMed](#)]
107. Aljaafari, M.; Alhosani, M.S.; Abushelaibi, A.; Kok-Song, L.; Swee-Hua, E.L. Essential Oils: Partnering with antibiotics. In *Essential Oils-Oils of Nature*; El-Shemy, H., Ed.; InTechOpen: London, UK, 2019; p. 13.
108. Benzaid, C.; Belmadani, A.; Djeribi, R.; Rouabhia, M. The effects of mentha × piperita essential oil on *C. Albicans* growth, transition, biofilm formation, and the expression of secreted aspartyl proteinases genes. *Antibiotics* **2019**, *8*, 10. [[CrossRef](#)]
109. Yang, S.-K.; Yusoff, K.; Ajat, M.; Thomas, W.; Abushelaibi, A.; Akseer, R.; Lim, S.-H.E.; Lai, K.-S. Disruption of KPC-producing *Klebsiella pneumoniae* membrane via induction of oxidative stress by cinnamon bark (*Cinnamomum verum* J. Presl) essential oil. *PLoS ONE* **2019**, *14*, e0214326. [[CrossRef](#)]
110. Shushizadeh, M.R.; Behroozi, S.; Behfar, A.A.; Nazemi, M. Antibacterial activity and Gc-Mass analysis of organic extract From Persian Gulf *Haliclona* sp. *Pharmacophore* **2018**, *9*, 19–24.
111. Okada, Y.; Matsunaga, S.; Van Soest, R.W.M.; Fusetani, N. Nagahamide A, an Antibacterial Depsipeptide from the Marine Sponge *Theonella swinhoei*. *Org. Lett.* **2002**, *4*, 3039–3042. [[CrossRef](#)] [[PubMed](#)]
112. Araki, A.; Kubota, T.; Aoyama, K.; Mikami, Y.; Fromont, J.; Kobayashi, J. Nagelamides Q and R, Novel Dimeric Bromopyrrole Alkaloids from Sponges *Agelas* sp. *Org. Lett.* **2009**, *11*, 1785–1788. [[CrossRef](#)] [[PubMed](#)]
113. Campana, R.; Favi, G.; Baffone, W.; Lucarini, S. Marine alkaloid 2,2-bis(6-bromo-3-indolyl) Ethylamine and its Synthetic Derivatives Inhibit Microbial Biofilms Formation and Disaggregate Developed Biofilms. *Microorganisms* **2019**, *7*, 28. [[CrossRef](#)]
114. Gelderblom, H.R. Structure and classification of viruses. In *Medical Microbiology*; Baron, S., Ed.; The University of Texas Medical Branch at Galveston: Galveston, TX, USA, 1996.
115. Drexler, M. *What You Need to Know About Infectious Disease*; National Academy of Sciences: Washington, DC, USA, 2010; ISBN 9780309161398.
116. Yamashita, A.; Fujimoto, Y.; Tamaki, M.; Setiawan, A.; Tanaka, T.; Okuyama-dobashi, K.; Kasai, H.; Watashi, K.; Wakita, T.; Toyama, M.; et al. Identification of Antiviral Agents Targeting Hepatitis B Virus Promoter from Extracts of Indonesian Marine Organisms by a Novel Cell-based Screening Assay. *Mar. Drugs* **2015**, *13*, 6759–6773. [[CrossRef](#)]
117. Salam, K.A.; Furuta, A.; Noda, N.; Tsuneda, S.; Sekiguchi, Y.; Tanaka, J.; Akimitsu, N. Inhibition of Hepatitis C Virus NS3 Helicase by Manoalide. *J. Nat. Prod.* **2012**, *75*, 650–654. [[CrossRef](#)] [[PubMed](#)]
118. Salam, K.A.; Akimitsu, N. Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives. *BioMed Res. Int.* **2013**, *2013*. [[CrossRef](#)] [[PubMed](#)]

119. Salam, K.A.; Furuta, A.; Noda, N.; Tsuneda, S.; Sekiguchi, Y.; Yamashita, A.; Moriishi, K.; Nakakoshi, M.; Tsubuki, M.; Tani, H.; et al. Psammaphin A Inhibits Hepatitis C Virus NS3 Helicase. *J. Nat. Med.* **2013**, *67*, 765–772. [[CrossRef](#)]
120. Kubota, T.; Kurimoto, S.I.; Kobayashi, J. The Manzamine Alkaloids. In *Alkaloids: Chemistry and Biology*; Elsevier Inc.: Amsterdam, The Netherlands, 2020; Volume 84, pp. 1–124, ISBN 9780128209820.
121. El Sayed, K.A.; Kelly, M.; Kara, U.A.K.; Ang, K.K.H.; Katsuyama, I.; Dunbar, D.C.; Khan, A.A.; Hamann, M.T. New Manzamine Alkaloids with Potent Activity against Infectious Diseases. *J. Am. Chem. Soc.* **2001**, *123*, 1804–1808. [[CrossRef](#)]
122. Palem, J.R.; Bedadala, G.R.; El Sayed, K.A.; Hsia, S.C.V. Manzamine A as a Novel Inhibitor of Herpes Simplex Virus type-1 Replication in Cultured Corneal Cells. *Planta Med.* **2011**, *77*, 46–51. [[CrossRef](#)]
123. Fan, G.; Li, Z.; Shen, S.; Zeng, Y.; Yang, Y.; Xu, M.; Bruhn, T.; Bruhn, H.; Morschhäuser, J.; Bringmann, G.; et al. Baculiferins A–O, O-sulfated Pyrrole Alkaloids with Anti-HIV-1 Activity, from the Chinese Marine Sponge *Iotrochota baculifera*. *Bioorganic Med. Chem.* **2010**, *18*, 5466–5474. [[CrossRef](#)] [[PubMed](#)]
124. Shin, H.J.; Rashid, M.A.; Cartner, L.K.; Bokesch, H.R.; Wilson, J.A.; McMahon, J.B.; Gustafson, K.R. Stelletapeptins A and B, HIV-Inhibitory Cyclic Depsipeptides from the Marine Sponge *Stelletta* sp. *Tetrahedron Lett.* **2015**, *56*, 4215–4219. [[CrossRef](#)] [[PubMed](#)]
125. Janbon, G.; Quintin, J.; Lanternier, F.; d’Enfert, C. Studying fungal pathogens of humans and fungal infections: Fungal diversity and diversity of approaches. *Genes Immun.* **2019**, *20*, 403–414. [[CrossRef](#)]
126. Garcia-Rubio, R.; de Oliveira, H.C.; Rivera, J.; Trevijano-Contador, N. The Fungal Cell Wall: *Candida*, *Cryptococcus*, and *Aspergillus* Species. *Front. Microbiol.* **2020**, *10*, 1–13. [[CrossRef](#)]
127. Watanadilok, R.; Sonchaeng, P.; Kijjoa, A.; Damas, A.M.; Gales, L.; Silva, A.M.S.; Herz, W. Tetillapyrone and Nortetillapyrone, Two Unusual Hydroxypyran-2-ones from the Marine Sponge *Tetilla japonica*. *J. Nat. Prod.* **2001**, *64*, 1056–1058. [[CrossRef](#)]
128. Wattanadilok, R.; Sawangwong, P.; Rodrigues, C.; Cidade, H.; Pinto, M.; Pinto, E.; Silva, A.; Kijjoa, A. Antifungal Activity Evaluation of the Constituents of *Haliclona baeri* and *Haliclona cymaeformis*, Collected from the Gulf of Thailand. *Mar. Drugs* **2007**, *5*, 40–51. [[CrossRef](#)]
129. Yu, H.B.; Liu, X.F.; Xu, Y.; Gan, J.H.; Jiao, W.H.; Shen, Y.; Lin, H.W. Woodylides A–C, New Cytotoxic Linear Polyketides from the South China Sea Sponge *Plakortis simplex*. *Mar. Drugs* **2012**, *10*, 1027–1036. [[CrossRef](#)]
130. Youssef, D.T.A.; Shaala, L.A.; Mohamed, G.A.; Badr, J.M.; Bamanie, F.H.; Ibrahim, S.R.M. Theonellamide G, a Potent Antifungal and Cytotoxic Bicyclic Glycopeptide from the Red Sea Marine Sponge *Theonella swinhoei*. *Mar. Drugs* **2014**, *12*, 1911–1923. [[CrossRef](#)]
131. Youssef, D.T.A.; Mooberry, S.L. Hurghadolide A and Swinholide I, Potent Actin-Microfilament Disrupters from the Red Sea Sponge *Theonella swinhoei*. *J. Nat. Prod.* **2006**, *69*, 154–157. [[CrossRef](#)] [[PubMed](#)]
132. Angawi, R.F.; Bavestrello, G.; Calcinai, B.; Dien, H.A.; Donnarumma, G.; Tufano, M.A.; Paoletti, I.; Grimaldi, E.; Chianese, G.; Fattorusso, E.; et al. Aurantoside J: A New Tetramic Acid Glycoside from *Theonella swinhoei*. Insights into the Antifungal Potential of Aurantosides. *Mar. Drugs* **2011**, *9*, 2809–2817. [[CrossRef](#)]
133. Ju, E.; Latif, A.; Kong, C.S.; Seo, Y.; Lee, Y.J.; Dalal, S.R.; Cassera, M.B.; Kingston, D.G.I. Antimalarial Activity of the Isolates from the Marine Sponge *Hyrtios erectus* against the Chloroquine-resistant Dd2 Strain of *Plasmodium falciparum*. *Z. Naturforsch. Sect. C J. Biosci.* **2018**, *73*, 397–400. [[CrossRef](#)] [[PubMed](#)]
134. Faruk, M.A.R.; Sarker, M.M.R.; Alam, M.J.; Kabir, M.B. Economic Loss from Fish Diseases on Rural Freshwater Aquaculture of Bangladesh. *Pakistan J. Biol. Sci.* **2004**, *7*, 2086–2091.
135. Mishra, S.; Das, R.; Swain, P. Status of Fish Diseases in Aquaculture and Assessment of Economic Loss due to Disease. In *Contemporary Trends in Fisheries and Aquaculture*; Rao, P., Pandey, B., Pandey, P., Joshi, B.D., Eds.; Today and Tomorrow’s Printers and Publishers: New Delhi, India, 2018.
136. Ismail, N.E.D.A.; Atta, N.S.; Aziz, A.E.; Ahmed, M. Oral Vaccination of Nile Tilapia (*Oreochromis niloticus*) against Motile *Aeromonas Septicaemia*. *Nat. Sci.* **2010**, *8*, 21–26.
137. Toranzo, A.E.; Magariños, B.; Romalde, J.L. A review of the main bacterial fish diseases in mariculture systems. *Aquaculture* **2005**, *246*, 37–61. [[CrossRef](#)]
138. Sonia, G.A.S.; Lipton, A.P.; Raj, R.P. Antibacterial activity of marine sponge extracts towards fish pathogenic bacteria. *ISR J. Aquac.* **2008**, *60*, 172–176.
139. Lee, Y.K.; Lee, J.-H.; Lee, H.K. Microbial Symbiosis in Marine Sponges. *J. Microbiol.* **2001**, *39*, 254–264.
140. Wahyudi, A.T.; Priyanto, J.A.; Maharsiwi, W.; Astuti, R.I. Screening and characterization of sponge-associated bacteria producing bioactive compounds anti-vibrio sp. *Am. J. Biochem. Biotechnol.* **2018**, *14*, 221–229. [[CrossRef](#)]
141. Mora-Cristancho, J.A.; Arévalo-Ferro, C.; Ramos, F.A.; Tello, E.; Duque, C.; Lhullier, C.; Falkenberg, M.; Schenkelc, E.P. Antifouling activities against colonizer marine bacteria of extracts from marine invertebrates collected in the Colombian Caribbean sea and on the Brazilian coast (Santa Catarina). *Z. Naturforsch. Sect. C J. Biosci.* **2011**, *66C*, 515–526. [[CrossRef](#)]
142. Wright, A.D.; McCluskey, A.; Robertson, M.J.; MacGregor, K.A.; Gordon, C.P.; Guenther, J. Anti-malarial, Anti-algal, Anti-tubercular, Anti-bacterial, Anti-photosynthetic, and Anti-fouling Activity of Diterpene and Diterpene Isonitriles from the Tropical Marine sponge *Cymbastela hooperi*. *Org. Biomol. Chem.* **2011**, *9*, 400–407. [[CrossRef](#)] [[PubMed](#)]
143. Mol, R.R.; Lipton, A.; Thankamani, V. Antibacterial and Antifouling Activity of the Marine Sponge *Callyspongia diffusa* Collected from South-west Coast of India. *Int. J. Biochem. Biotechnol.* **2016**, *12*, 33–42.

144. Matsunaga, S.; Kobayashi, H.; Van Soest, R.W.M.; Fusetani, N. Novel Bromotyrosine Derivatives That Inhibit Growth of the Fish Pathogenic Bacterium *Aeromonas hydrophila*, from a Marine Sponge *Hexadella* sp. 1 *Hexadella* sp. collected in southern Japan exhibited *Aeromonas hydrophila*, which causes hemorrhagic septio. *J. Org. Chem.* **2005**, *70*, 1893–1896. [[CrossRef](#)]
145. Huang, X.; Kong, F.; Zhou, S.; Huang, D.; Zheng, J.; Zhu, W. *Streptomyces tirandamycinicus* sp. Nov., a Novel Marine Sponge-derived Actinobacterium with Antibacterial Potential against *Streptococcus agalactiae*. *Front. Microbiol.* **2019**, *10*, 1–11. [[CrossRef](#)]
146. Devi, P.; Ravichandran, S.; Ribeiro, M.; Ciavatta, M. Antifungal Potential of Marine Sponge Extract against Plant and Fish Pathogenic Fungi. *Oceanogr. Open Access* **2013**, *01*, 10–13.
147. Kurnianda, V.; Khairunnisa; Winanda, A.; Mauliza, A.; Ulfah, M.; Nurfadillah; Ishida, R.; Kobayashi, M. Polyhydroxy Isocopalane from Indonesian's Marine Sponge *Callyspongia* Sp. as Anti-White Spot Syndrome Virus from *Litopenaeus vannamei*. *J. Pharmacogn. Nat. Prod.* **2017**, *3*, 2–4. [[CrossRef](#)]
148. Xu, Y.; Li, N.; Jiao, W.H.; Wang, R.P.; Peng, Y.; Qi, S.H.; Song, S.J.; Chen, W.S.; Lin, H.W. Antifouling and Cytotoxic Constituents from the South China Sea Sponge *Acanthella cavernosa*. *Tetrahedron* **2012**, *68*, 2876–2883. [[CrossRef](#)]
149. Sjögren, M.; Dahlström, M.; Hedner, E.; Jonsson, P.R.; Vik, A.; Gundersen, L.L.; Bohlin, L. Antifouling Activity of the Sponge Metabolite Agelasine D and Synthesised Analogs on *Balanus improvisus*. *Biofouling* **2008**, *24*, 251–258. [[CrossRef](#)]
150. Blihoghe, D.; Manzo, E.; Villela, A.; Cutignano, A.; Picariello, G.; Faimali, M.; Fontana, A. Evaluation of the Antifouling Properties of 3-alkylpyridine Compounds. *Biofouling* **2011**, *27*, 99–109. [[CrossRef](#)]
151. Tsoukatou, M.; Hellio, C.; Vagias, C.; Harvala, C.; Roussis, V. Chemical Defense and Antifouling Activity of Three Mediterranean Sponges of the Genus *Ircinia*. *Z. Naturforsch. Sect. C J. Biosci.* **2002**, *57*, 161–171. [[CrossRef](#)]
152. Nguyen, X.C.; Longeon, A.; Pham, V.C.; Urvois, F.; Bressy, C.; Van Trinh, T.T.; Nguyen, H.N.; Phan, V.K.; Chau, V.M.; Briand, J.F.; et al. Antifouling 26,27-cyclosterols from the Vietnamese Marine Sponge *Xestospongia testudinaria*. *J. Nat. Prod.* **2013**, *76*, 1313–1318. [[CrossRef](#)]
153. Zhi, X.-Y.; Yao, J.-C.; Tang, S.-K.; Huang, Y.; Li, H.-W.; Li, W.-J. The Futasine Pathway Played an Important Role in Menaquinone Biosynthesis during Early Prokaryote Evolution. *Genome Biol. Evol.* **2014**, *6*, 149–160. [[CrossRef](#)] [[PubMed](#)]
154. Ogasawara, Y.; Kondo, K.; Ikeda, A.; Harada, R.; Dairi, T. Identification of Tirandamycins as Specific Inhibitors of the Futasine Pathway. *J. Antibiot.* **2017**, *70*, 798–800. [[CrossRef](#)]
155. Kiran, G.S.; Lipton, A.N.; Priyadharshini, S.; Anitha, K.; Suárez, L.E.C.; Arasu, M.V.; Choi, K.C.; Selvin, J.; Al-Dhabi, N.A. Antiadhesive Activity of Poly-hydroxy Butyrate Biopolymer from a Marine Brevibacterium *casei* MSI04 against Shrimp Pathogenic *Vibrios*. *Microb. Cell Fact.* **2014**, *13*, 1–12. [[CrossRef](#)] [[PubMed](#)]
156. Xu, P.; Ding, L.; Wei, J.; Li, Q.; Gui, M.; He, X.; Su, D.; He, S.; Jin, H. A New Aquatic Pathogen Inhibitor Produced by the Marine Fungus *Aspergillus* sp. LS116. *Aquaculture* **2020**, *520*, 734670. [[CrossRef](#)]
157. Hadas, E.; Shpigel, M.; Ilan, M. Sea Ranching of the Marine Sponge *Negombata magnifica* (Demospongiae, Latrunculiidae) as a First Step for Latrunculin B Mass Production. *Aquaculture* **2005**, *244*, 159–169. [[CrossRef](#)]
158. Zhu, F.; Twan, W.H.; Tseng, L.C.; Peng, S.H.; Hwang, J.S. First Detection of White Spot Syndrome Virus (WSSV) in the Mud Shrimp *Austinoergia edulis* in Taiwan. *Sci. Rep.* **2019**, *9*. [[CrossRef](#)] [[PubMed](#)]
159. Bannister, J.; Sievers, M.; Bush, F.; Bloecher, N. Biofouling in Marine Aquaculture: A Review of Recent Research and Developments. *Biofouling* **2019**, *35*, 631–648. [[CrossRef](#)]
160. Hedner, E.; Sjögren, M.; Hodzic, S.; Andersson, R.; Göransson, U.; Jonsson, P.R.; Bohlin, L. Antifouling Activity of a Dibrominated Cyclopeptide from the Marine Sponge *Geodia barretti*. *J. Nat. Prod.* **2004**, *67*, 368–372.
161. Hertiani, T.; Edrada-Ebel, R.A.; Ortlepp, S.; van Soest, R.W.M.; de Voogd, N.J.; Wray, V.; Hentschel, U.; Kozytska, S.; Müller, W.E.G.; Prosch, P. From Anti-fouling to Biofilm Inhibition: New Cytotoxic Secondary Metabolites from Two Indonesian Agelas Sponges. *Bioorg. Med. Chem.* **2010**, *18*, 1297–1311. [[CrossRef](#)] [[PubMed](#)]
162. Tsoukatou, M.; Maréchal, J.P.; Hellio, C.; Novaković, I.; Tufegdžic, S.; Sladić, D.; Gašić, M.J.; Clare, A.S.; Vagias, C.; Roussis, V. Evaluation of the Activity of the Sponge Metabolites Avarol and Avarone and their Synthetic Derivatives against Fouling Micro- and Macroorganisms. *Molecules* **2007**, *12*, 1022–1034. [[CrossRef](#)]
163. Stewart, M.; Depree, C.; Thompson, K.J. Natural Product Communications Antifouling Sesterterpenes from the New Zealand Marine Sponge *Semitaspongia bactriana*. *Nat. Prod. Commun.* **2009**, *4*, 331–336.
164. Hellio, C.; Tsoukatou, M.; Maréchal, J.-P.; Aldred, N.; Beaupoil, C.; Clare, A.S.; Vagias, C.; Roussis, V. Inhibitory Effects of Mediterranean Sponge Extracts and Metabolites on Larval Settlement of the Barnacle *Balanus amphitrite*. *Mar. Biotechnol.* **2005**, *7*, 297–305. [[CrossRef](#)] [[PubMed](#)]
165. Gunasekera, S.P.; Cross, S.S. Fistularin 3 and 11-ketofistularin 3. Feline leukemia virus active bromotyrosine metabolites from the marine sponge *Aplysina archeri*. *J. Nat. Prod.* **1992**, *55*, 509–512. [[CrossRef](#)]
166. Luduena, R.F.; Roach, M.C.; Prasad, V.; Pettit, G.R. Interaction of Halichondrin B and Homohalichondrin B with Bovine Brain Tubulin. *Biochem. Pharmacol.* **1993**, *45*, 421–427. [[CrossRef](#)]
167. Laport, M.S.; Marinho, P.R.; da Silva Santos, O.C.; de Almeida, P.; Romanos, M.T.V.; Muricy, G.; Brito, M.A.V.P.; Giambiagi-deMarval, M. Antimicrobial activity of marine sponges against coagulase-negative staphylococci isolated from bovine mastitis. *Vet. Microbiol.* **2012**, *155*, 362–368. [[CrossRef](#)]
168. Kohn, L.K.; Porto, P.; Bianchi, B.; Santos, M.; Berlinck, R.; Arns, C. NOR-Batzelladine L from the sponge *Monanchora* sp. displays antiviral activity against Herpes simplex virus type 1. *Planta Med.* **2012**, *78*, CL27. [[CrossRef](#)]

169. El-Demerdash, A.; Atanasov, A.G.; Bishayee, A.; Abdel-Mogib, M.; Hooper, J.N.A.; Al-Mourabit, A. Batzella, Crambe and Monanchora: Highly prolific marine sponge genera yielding compounds with potential applications for cancer and other therapeutic areas. *Nutrients* **2018**, *10*, 33. [[CrossRef](#)] [[PubMed](#)]
170. Farrugia, M.; Trotter, N.; Vijayarathy, S.; Salim, A.A.; Khalil, Z.G.; Lacey, E.; Capon, R.J. Isolation and Synthesis of N-acyladenine and Adenosine Alkaloids from a Southern Australian Marine Sponge, *Phoriospongia* sp. *Tetrahedron Lett.* **2014**, *55*, 5902–5904. [[CrossRef](#)]
171. Patil, A.D.; Freyer, A.J.; Carte, B.; Johnson, R.K.; Lahouratate, P. Plakortides, Novel Cyclic Peroxides from the Sponge *Plakortis halichondrioides*. Activators of Cardiac SR-Ca²⁺ Pumping ATPase. *J. Nat. Prod.* **1996**, *59*, 219–223. [[CrossRef](#)]
172. Wei, L.; Zhu, S.; Yan, X.; Wang, J.; Zhang, C.; Liu, S.; She, R.; Hu, F.; Quan, R.; Liu, J.; et al. Avian Metapneumovirus subgroup C infection in chickens, China. *Emerg. Infect. Dis.* **2013**, *19*, 1092–1094. [[CrossRef](#)]
173. Hartmann, S.; Sid, H.; Rautenschlein, S. Avian metapneumovirus infection of chicken and turkey tracheal organ cultures: Comparison of virus–host interactions. *Avian Pathol.* **2015**, *44*, 480–489. [[CrossRef](#)] [[PubMed](#)]
174. Pyörälä, S.; Taponen, S. Coagulase-negative staphylococci-Emerging mastitis pathogens. *Vet. Microbiol.* **2009**, *134*, 3–8. [[CrossRef](#)]
175. Bande, F.; Arshad, S.S.; Hassan, L.; Zakaria, Z. Molecular detection, phylogenetic analysis, and identification of transcription motifs in feline leukemia virus from naturally infected cats in Malaysia. *Vet. Med. Int.* **2014**, *2014*. [[CrossRef](#)] [[PubMed](#)]
176. Little, S.; Bienzle, D.; Carioto, L.; Chisholm, H.; Brien, E.O.; Scherk, M. Feline leukemia virus and feline immunodeficiency virus in Canada: Recommendations for testing and management. *Can. Vet. J.* **2011**, *52*, 849–855.
177. Carmichael, K.P.; Bienzle, D.; McDonnell, J.J. Feline Leukemia Virus-associated Myelopathy in Cats. *Vet. Pathol.* **2002**, *39*, 536–545. [[CrossRef](#)]
178. Esposito, G.; Mai, L.H.; Longeon, A.; Mangoni, A.; Durieu, E.; Meijer, L.; Van Soest, R.; Costantino, V.; Bourguet-Kondracki, M.L. A collection of bioactive nitrogen-containing molecules from the marine sponge *acanthostrongylophora ingens*. *Mar. Drugs* **2019**, *17*, 472. [[CrossRef](#)]
179. Zhou, R.; Liao, X.; Li, H.; Li, J.; Feng, P.; Zhao, B.X.; Xu, S. Isolation and Synthesis of Misszrtine A: A Novel Indole Alkaloid from Marine Sponge-Associated *Aspergillus* sp. SCSIO XWS03F03. *Front. Chem.* **2018**, *6*, 1–7. [[CrossRef](#)] [[PubMed](#)]
180. Taufa, T.; Singh, A.J.; Harland, C.R.; Patel, V.; Jones, B.; Halafihi, T.; Miller, J.H.; Keyzers, R.A.; Northcote, P.T. Zampanolides B-E from the Marine Sponge *Cacospongia mycofijiensis*: Potent Cytotoxic Macrolides with Microtubule-Stabilizing Activity. *J. Nat. Prod.* **2018**, *81*, 2539–2544. [[CrossRef](#)]
181. Balansa, W.; Mettal, U.; Wuisan, Z.G.; Plubrukarn, A.; Ijong, F.G.; Liu, Y.; Schäberle, T.F. A New Sesquiterpenoid Aminoquinone from an Indonesian Marine Sponge. *Mar. Drugs* **2019**, *17*, 158. [[CrossRef](#)] [[PubMed](#)]
182. Yu, H.B.; Yin, Z.F.; Gu, B.B.; Zhang, J.P.; Wang, S.P.; Yang, F.; Lin, H.W. Cytotoxic Meroterpenoids from the Marine Sponge *Dactylospongia elegans*. *Nat. Prod. Res.* **2019**, 1–7. [[CrossRef](#)] [[PubMed](#)]
183. Shubina, L.K.; Makarieva, T.N.; Denisenko, V.A.; Popov, R.S.; Dyshlovoy, S.A.; Grebnev, B.B.; Dmitrenok, P.S.; von Amsberg, G.; Stonik, V.A. Gracilosulfates A–G, Monosulfated Polyoxygenated Steroids from the Marine Sponge *Haliclona gracilis*. *Mar. Drugs* **2020**, *18*, 454. [[CrossRef](#)]
184. Campos, P.; Pichon, E.; Moriou, C.; Clerc, P.; Tr, R.; Frederich, M.; De Voogd, N.; Hellio, C.; Gauvin-bialecki, A.; Al-mourabit, A. New Antimalarial and Antimicrobial Tryptamine Derivatives from the Marine Sponge *Fascaplysinopsis reticulata*. *Mar. Drugs* **2019**, *17*, 167. [[CrossRef](#)]
185. Campos, P.E.; Herbette, G.; Chendo, C.; Clerc, P.; Tintillier, F.; Voogd, N.J.D.; Papanagnou, E.D.; Trougakos, I.P.; Jerabek, M.; Bignon, J.; et al. Osirisynes G–I, New Long-Chain Highly Oxygenated Polyacetylenes from the Mayotte Marine Sponge *Haliclona* sp. *Mar. Drugs* **2020**, *18*, 350. [[CrossRef](#)]
186. Nagabhishek, S.N.; Madankumar, A. A Novel Apoptosis-Inducing Metabolite Isolated from Marine Sponge Symbiont: *Monascus* sp. NMK7 Attenuates Cell Proliferation, Migration and ROS Stress-Mediated Apoptosis in Breast Cancer Cells. *RSC Adv.* **2019**, *9*, 5878–5890. [[CrossRef](#)]
187. Liu, P.; Panek, J.S. Total synthesis of (–)-mycalolide A. *J. Am. Chem. Soc.* **2000**, *122*, 1235–1236. [[CrossRef](#)]
188. Hayashi-Takanaka, Y.; Kina, Y.; Nakamura, F.; Yamazaki, S.; Harata, M.; van Soest, R.W.M.; Kimura, H.; Nakao, Y. Effect of Mycalolides Isolated from a Marine Sponge *Mycale* aff. *nullarosette* on Actin in Living Cells. *Sci. Rep.* **2019**, *9*, 1–9. [[CrossRef](#)]
189. Pang, X.; Lin, X.; Yang, J.; Zhou, X.; Yang, B.; Wang, J.; Liu, Y. Spiro-Phthalides and Isocoumarins Isolated from the Marine-Sponge-Derived Fungus *Setosphaeria* sp. SCSIO41009. *J. Nat. Prod.* **2018**, *81*, 1860–1868. [[CrossRef](#)]
190. Bashari, M.H.; Huda, F.; Tartila, T.S.; Shabrina, S.; Putri, T.; Qomarilla, N.; Atmaja, H.; Subhan, B.; Sudji, I.R.; Meiyanto, E. Bioactive Compounds in the Ethanol Extract of Marine Sponge *Stylissa carteri* Demonstrates Potential Anti-Cancer Activity in Breast Cancer Cells. *Asian Pacific J. Cancer Prev.* **2019**, *20*, 1199–1206. [[CrossRef](#)] [[PubMed](#)]
191. Tian, C.; Ni, J.; Chang, F.; Liu, S.; Xu, N.; Sun, W.; Xie, Y.; Guo, Y.; Ma, Y.; Yang, Z.; et al. Bio-Source of di-n-butyl Phthalate Production by Filamentous Fungi. *Sci. Rep.* **2016**, *6*, 19791. [[CrossRef](#)] [[PubMed](#)]
192. Barakat, K.M.; Beltagy, E.A. Bioactive Phthalate from Marine *Streptomyces ruber* EKH2 against Virulent Fish Pathogens. *Egypt. J. Aquat. Res.* **2015**, *41*, 49–56. [[CrossRef](#)]
193. Kalinovskaya, N.I.; Romanenko, L.A.; Kalinovskiy, A.I. Antibacterial Low-Molecular-Weight Compounds Produced by the Marine Bacterium *Rheinheimera japonica* KMM 9513T. *Antonie Leeuwenhoek Int. J. Gen. Mol. Microbiol.* **2017**, *110*, 719–726. [[CrossRef](#)]
194. Hoang, V.L.T.; Li, Y.; Kim, S.K. Cathepsin B Inhibitory Activities of Phthalates Isolated from a Marine *Pseudomonas* strain. *Bioorganic Med. Chem. Lett.* **2008**, *18*, 2083–2088. [[CrossRef](#)] [[PubMed](#)]

195. Hsieh, T.; Tsai, C.; Hsu, C.; Kuo, P.; Lee, J.; Chai, C.; Wang, S.; Tsai, E. Phthalates Induce Proliferation and Invasiveness of Estrogen Receptor-Negative Breast Cancer through the AhR/HDAC6/c-Myc Signaling Pathway. *FASEB J.* **2012**, *26*, 778–787. [[CrossRef](#)] [[PubMed](#)]
196. Sirpu Natesh, N.; Arumugam, M.; Karanam, G. Apoptotic Role of Marine Sponge Symbiont *Bacillus subtilis* NMK17 through the Activation of Caspase-3 in Human Breast Cancer Cell Line. *Mol. Biol. Rep.* **2018**, *45*, 2641–2651. [[CrossRef](#)]
197. Pagliara, P.; Barca, A.; Verri, T.; Caroppo, C. The Marine Sponge *Petrosia ficiformis* Harbors Different Cyanobacteria Strains with Potential Biotechnological Application. *J. Mar. Sci. Eng.* **2020**, *8*, 638. [[CrossRef](#)]
198. Kiran, G.S.; Hassan, S.; Sajayan, A.; Selvin, J. Quorum quenching compounds from natural sources. In *Bioresources and Bioprocess in Biotechnology*; Springer Nature: Singapore, 2017; pp. 351–363, ISBN 9789811042843.
199. Tang, K.; Zhang, X.H. Quorum quenching agents: Resources for antivirulence therapy. *Mar. Drugs* **2014**, *12*, 3245–3282. [[CrossRef](#)] [[PubMed](#)]
200. Uroz, S.; Dessaux, Y.; Oger, P. Quorum sensing and quorum quenching: The Yin and Yang of bacterial communication. *Chem-BioChem* **2009**, *10*, 205–216. [[CrossRef](#)]
201. Leadbetter, J.R.; Greenberg, E.P. Metabolism of acyl-homoserine lactone quorum-sensing signals by *Variovorax paradoxus*. *J. Bacteriol.* **2000**, *182*, 6921–6926. [[CrossRef](#)]
202. Plaza, A.; Gustchina, E.; Baker, H.L.; Kelly, M.; Bewley, C.A. Mirabamides A–D, depsipeptides from the sponge *Siliquariaspongia mirabilis* that inhibit HIV-1 fusion. *J. Nat. Prod.* **2007**, *70*, 1753–1760. [[CrossRef](#)] [[PubMed](#)]
203. Lerata, M.S.; D'Souza, S.; Sibuyi, N.R.S.; Dube, A.; Meyer, M.; Samaai, T.; Antunes, E.M.; Beukes, D.R. Encapsulation of variabilin in stearic acid solid lipid nanoparticles enhances its anticancer activity in vitro. *Molecules* **2020**, *25*, 930. [[CrossRef](#)]
204. Choi, K.; Lim, H.K.; Oh, S.R.; Chung, W.H.; Jung, J. Anticancer Effects of the Marine Sponge *Lipastrotethya* sp. Extract on Wild-Type and p53 Knockout HCT116 Cells. *Evid. Based Complement. Altern. Med.* **2017**, *2017*, 1–7. [[CrossRef](#)] [[PubMed](#)]
205. Calcabrini, C.; Catanzaro, E.; Bishayee, A.; Turrini, E.; Fimognari, C. Marine sponge natural products with anticancer potential: An updated review. *Mar. Drugs* **2017**, *15*, 310. [[CrossRef](#)] [[PubMed](#)]